Role	O
of	O
Egr-2	B-protein
in	O
up-regulation	O
of	O
Fas	B-protein
ligand	I-protein
in	O
normal	O
T	B-cell_type
cells	I-cell_type
and	O
aberrant	B-cell_type
double-negative	I-cell_type
lpr	I-cell_type
and	I-cell_type
gld	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
previously	O
identified	O
a	O
Fas	B-DNA
ligand	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
FLRE	B-DNA
)	O
in	O
the	O
Fas	B-DNA
ligand	I-DNA
(	I-DNA
fasL	I-DNA
)	I-DNA
promoter	I-DNA
that	O
binds	O
Egr	B-protein
family	I-protein
proteins	I-protein
and	O
demonstrated	O
that	O
Egr-3	B-protein
(	O
PILOT	B-protein
)	O
but	O
not	O
Egr-1	B-protein
(	O
NGFI-A	B-protein
,	O
Krox-24	B-protein
,	O
Tis-8	B-protein
,	O
and	O
Zif-268	B-protein
)	O
induces	O
transcription	O
of	O
fasL	B-protein
.	O

The	O
aberrant	B-cell_type
CD4	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
lpr/lpr	O
and	O
gld/gld	O
mice	O
,	O
which	O
have	O
mutations	O
in	O
the	O
genes	O
encoding	O
Fas	B-protein
and	O
FasL	B-protein
,	O
respectively	O
,	O
have	O
an	O
activated	O
phenotype	O
and	O
constitutively	O
express	O
high	O
levels	O
of	O
fasL	B-RNA
mRNA	I-RNA
,	O
prompting	O
us	O
to	O
ask	O
what	O
role	O
if	O
any	O
the	O
FLRE	B-DNA
and	O
Egr	B-protein
family	I-protein
proteins	I-protein
have	O
in	O
this	O
aberrant	O
expression	O
of	O
fasL	B-protein
.	O

Unstimulated	O
MRL-lpr/lpr	B-cell_line
and	I-cell_line
C3H-gld/gld	I-cell_line
CD4	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
constitutively	O
contained	O
high	O
levels	O
of	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
FLRE	B-DNA
.	O

Supershift	O
analysis	O
revealed	O
these	O
proteins	O
to	O
be	O
Egr-1	B-protein
and	O
Egr-2	B-protein
(	O
Krox-20	O
)	O
;	O
Egr-3	B-protein
was	O
not	O
detected	O
.	O

Activation	O
of	O
normal	B-cell_type
lymph	I-cell_type
node	I-cell_type
cells	I-cell_type
resulted	O
in	O
increased	O
expression	O
of	O
Egr-1	B-protein
,	I-protein
-2	I-protein
,	I-protein
and	I-protein
-3	I-protein
.	O

As	O
with	O
egr-3	B-DNA
,	O
expression	O
of	O
egr-2	B-DNA
was	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

Although	O
overexpressed	O
Egr-1	B-protein
was	O
ineffective	O
,	O
overexpressed	O
Egr-2	B-protein
was	O
as	O
potent	O
as	O
Egr-3	B-protein
in	O
inducing	O
fasL	B-DNA
promoter-dependent	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up-regulated	O
endogenous	O
fasL	B-RNA
mRNA	I-RNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

FasL-dependent	B-DNA
reporter	I-DNA
constructs	I-DNA
in	O
MRL-lpr/lpr	B-cell_line
and	I-cell_line
C3H-gld/gld	I-cell_line
CD4	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	B-DNA
family	I-DNA
binding	I-DNA
element	I-DNA
.	O

Thus	O
,	O
Egr-2	B-protein
,	O
in	O
addition	O
to	O
Egr-3	B-protein
,	O
regulates	O
FasL	B-protein
expression	O
in	O
activated	O
normal	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
Egr-2	B-protein
is	O
likely	O
to	O
play	O
a	O
direct	O
role	O
in	O
aberrant	O
fasL	B-protein
up-regulation	O
in	O
lpr/lpr	B-cell_line
and	I-cell_line
gld/gld	I-cell_line
CD4	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
Vol	NULL
.	NULL

274	NULL
,	NULL
No	NULL
.	NULL

5	NULL
,	NULL
Issue	NULL
of	NULL
January	NULL
29	NULL
,	NULL
pp	NULL
.	NULL

3222-3227	NULL
,	NULL
1999	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Role	NULL
of	NULL
Egr-2	NULL
in	NULL
Up-regulation	NULL
of	NULL
Fas	NULL
Ligand	NULL
in	NULL
Normal	NULL
T	NULL
Cells	NULL
and	NULL
Aberrant	NULL
Double-negative	NULL
Ipr	NULL
and	NULL
gid	NULL
T	NULL
Cells*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
September	NULL
2	NULL
,	NULL
1998	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
November	NULL
13	NULL
,	NULL
1998	NULL
)	NULL
Paul	NULL
R.	NULL
Mittelstadt	NULL
and	NULL
Jonathan	NULL
D.	NULL
Ashwell	NULL
$	NULL
From	NULL
the	NULL
Laboratory	NULL
of	NULL
Immune	NULL
Cell	NULL
Biology	NULL
,	NULL
NCI	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892-1152	NULL
We	NULL
previously	NULL
identified	NULL
a	NULL
Fas	NULL
ligand	NULL
regulatory	NULL
element	NULL
(	NULL
FLRE	NULL
)	NULL
in	NULL
the	NULL
Fas	NULL
ligand	NULL
(	NULL
fasL	NULL
)	NULL
promoter	NULL
that	NULL
binds	NULL
Egr	NULL
family	NULL
proteins	NULL
and	NULL
demonstrated	NULL
that	NULL
Egr-3	NULL
(	NULL
PILOT	NULL
)	NULL
but	NULL
not	NULL
Egr-1	NULL
(	NULL
NGFI-A	NULL
,	NULL
Krox-24	NULL
,	NULL
Tis-8	NULL
,	NULL
and	NULL
Zif-268	NULL
)	NULL
induces	NULL
transcription	NULL
of	NULL
fasL	NULL
.	NULL

The	NULL
aberrant	NULL
CD4TCD8~	NULL
T	NULL
cells	NULL
from	NULL
Ipr/ipr	NULL
and	NULL
gid/glid	NULL
mice	NULL
,	NULL
which	NULL
have	NULL
mutations	NULL
in	NULL
the	NULL
genes	NULL
encoding	NULL
Fas	NULL
and	NULL
FasL	NULL
,	NULL
respectively	NULL
,	NULL
have	NULL
an	NULL
activated	NULL
phenotype	NULL
and	NULL
constitutively	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
fasL	NULL
mRNA	NULL
,	NULL
prompting	NULL
us	NULL
to	NULL
ask	NULL
what	NULL
role	NULL
if	NULL
any	NULL
the	NULL
FLRE	NULL
and	NULL
Egr	NULL
family	NULL
proteins	NULL
have	NULL
in	NULL
this	NULL
aberrant	NULL
expression	NULL
of	NULL
fasL	NULL
.	NULL

Unstimulated	NULL
MRL-Ipr/ipr	NULL
and	NULL
C3H-gid/gld	NULL
CD4~-CD8~	NULL
T	NULL
cells	NULL
constitutively	NULL
contained	NULL
high	NULL
levels	NULL
of	NULL
two	NULL
proteins	NULL
that	NULL
bound	NULL
to	NULL
the	NULL
FLRE	NULL
.	NULL

Supershift	NULL
analysis	NULL
revealed	NULL
these	NULL
proteins	NULL
to	NULL
be	NULL
Egr-1	NULL
and	NULL
Egr-2	NULL
(	NULL
Krox-20	NULL
)	NULL
;	NULL
Egr-3	NULL
was	NULL
not	NULL
detected	NULL
.	NULL

Activation	NULL
of	NULL
normal	NULL
lymph	NULL
node	NULL
cells	NULL
resulted	NULL
in	NULL
increased	NULL
expression	NULL
of	NULL
Egr-1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
.	NULL

As	NULL
with	NULL
egr-3	NULL
,	NULL
expression	NULL
of	NULL
egr-2	NULL
was	NULL
blocked	NULL
by	NULL
cyclosporin	NULL
A	NULL
.	NULL

Although	NULL
overexpressed	NULL
Egr-1	NULL
was	NULL
ineffective	NULL
,	NULL
overexpressed	NULL
Egr-2	NULL
was	NULL
as	NULL
potent	NULL
as	NULL
Egr-3	NULL
in	NULL
inducing	NULL
fasL	NULL
promoter-dependent	NULL
reporter	NULL
constructs	NULL
in	NULL
T	NULL
cell	NULL
hybri-domas	NULL
and	NULL
Hela	NULL
cells	NULL
,	NULL
and	NULL
both	NULL
up-regulated	NULL
endoge-nous	NULL
fasL	NULL
mRNA	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

FasL-dependent	NULL
reporter	NULL
constructs	NULL
in	NULL
MRL-Ipr/ipr	NULL
and	NULL
C3H-gld/gid	NULL
CD4	NULL
-CD8~	NULL
T	NULL
cells	NULL
were	NULL
constitutively	NULL
active	NULL
,	NULL
and	NULL
this	NULL
activity	NULL
was	NULL
largely	NULL
prevented	NULL
by	NULL
mutation	NULL
of	NULL
the	NULL
critical	NULL
Egr	NULL
family	NULL
binding	NULL
element	NULL
.	NULL

Thus	NULL
,	NULL
Egr-2	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
Egr-3	NULL
,	NULL
regulates	NULL
FasL	NULL
expression	NULL
in	NULL
activated	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
Egr-2	NULL
is	NULL
likely	NULL
to	NULL
play	NULL
a	NULL
direct	NULL
role	NULL
in	NULL
aberrant	NULL
fasL	NULL
up-regulation	NULL
in	NULL
Ipr/ipr	NULL
and	NULL
gid/gld	NULL
CD4_-CD8~_	NULL
T	NULL
cells	NULL
.	NULL

Apoptotic	NULL
death	NULL
of	NULL
T	NULL
cells	NULL
at	NULL
the	NULL
conclusion	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
is	NULL
critical	NULL
for	NULL
homeostasis	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
-mediated	NULL
'	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
induces	NULL
the	NULL
transcription	NULL
and	NULL
synthesis	NULL
of	NULL
the	NULL
cell	NULL
surface	NULL
molecule	NULL
Fas	NULL
and	NULL
its	NULL
ligand	NULL
,	NULL
FasL	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Although	NULL
activated	NULL
T	NULL
cells	NULL
are	NULL
initially	NULL
resistant	NULL
to	NULL
death	NULL
signals	NULL
mediated	NULL
by	NULL
Fas	NULL
,	NULL
prolonged	NULL
activation	NULL
increases	NULL
their	NULL
sensitivity	NULL
,	NULL
presumably	NULL
owing	NULL
to	NULL
down-regulation	NULL
of	NULL
such	NULL
cellular	NULL
inhibitors	NULL
of	NULL
the	NULL
Fas/FADD/caspase	NULL
8	NULL
cascade	NULL
as	NULL
c-FLIPs	NULL
(	NULL
2	NULL
)	NULL
and	NULL
IAPs	NULL
(	NULL
8	NULL
,	NULL
4	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
Ipr	NULL
and	NULL
gid	NULL
mutations	NULL
result	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
function	NULL
of	NULL
Fas	NULL
(	NULL
5	NULL
)	NULL
and	NULL
FasL	NULL
(	NULL
6-8	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

As	NULL
a	NULL
result	NULL
,	NULL
these	NULL
mice	NULL
lack	NULL
a	NULL
functional	NULL
Fas	NULL
death	NULL
pathway	NULL
,	NULL
preventing	NULL
deletion	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
*	NULL
The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1784	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

J	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
801-496-4981	NULL
;	NULL
Fax	NULL
:	NULL
301-402-4844	NULL
;	NULL
E-mail	NULL
:	NULL
jda	NULL
@	NULL
Box-j.nih.gov	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
DN	NULL
,	NULL
double-neg-ative	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
FLRE	NULL
,	NULL
fasL	NULL
regulatory	NULL
element	NULL
;	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
RT	NULL
,	NULL
reverse	NULL
transcriptase	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
MOPS	NULL
,	NULL
3-	NULL
(	NULL
N-morpholino	NULL
)	NULL
propanesulfonic	NULL
acid	NULL
;	NULL
GAPDH	NULL
,	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
.	NULL

3222	NULL
leading	NULL
to	NULL
the	NULL
accumulation	NULL
of	NULL
large	NULL
numbers	NULL
of	NULL
abnormal	NULL
CD4~CD8~	NULL
,	NULL
B220*	NULL
,	NULL
TCR*	NULL
lymph	NULL
node	NULL
cells	NULL
(	NULL
referred	NULL
to	NULL
as	NULL
double-negative	NULL
(	NULL
DN	NULL
)	NULL
T	NULL
cells	NULL
)	NULL
.	NULL

Humans	NULL
with	NULL
defects	NULL
in	NULL
Fas-mediated	NULL
killing	NULL
have	NULL
an	NULL
lpr-like	NULL
syndrome	NULL
,	NULL
with	NULL
accumulation	NULL
of	NULL
DN	NULL
(	NULL
TCR*CD4~CD8~	NULL
)	NULL
T	NULL
lymphocytes	NULL
and	NULL
autoimmune	NULL
phenomena	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

MRL	NULL
(	NULL
Ipr	NULL
)	NULL
and	NULL
C3H-glid/gld	NULL
(	NULL
gld	NULL
)	NULL
cells	NULL
have	NULL
many	NULL
features	NULL
characteristic	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
their	NULL
presence	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
development	NULL
of	NULL
autoim-munity	NULL
.	NULL

As	NULL
a	NULL
presumed	NULL
consequence	NULL
of	NULL
being	NULL
chronically	NULL
acti-vated	NULL
,	NULL
Ipr	NULL
and	NULL
gld	NULL
lymph	NULL
node	NULL
cells	NULL
constitutively	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
fasL	NULL
mRNA	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Control	NULL
of	NULL
fasL	NULL
transcription	NULL
in	NULL
different	NULL
settings	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
several	NULL
transcription	NULL
factors	NULL
.	NULL

For	NULL
example	NULL
,	NULL
fasL	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
DNA-damaging	NULL
agents	NULL
such	NULL
as	NULL
UV	NULL
irradiation	NULL
or	NULL
topoisomerase	NULL
inhibitors	NULL
(	NULL
14	NULL
)	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
mutant	NULL
reporter	NULL
constructs	NULL
have	NULL
indicated	NULL
that	NULL
control	NULL
of	NULL
fasL	NULL
transcription	NULL
can	NULL
be	NULL
attributed	NULL
directly	NULL
to	NULL
NF-	NULL
«	NULL
B-	NULL
and	NULL
AP-l-binding	NULL
sites	NULL
located	NULL
more	NULL
than	NULL
1	NULL
kilobase	NULL
upstream	NULL
of	NULL
the	NULL
coding	NULL
region	NULL
.	NULL

Overexpression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
form	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
inhibitor	NULL
I-	NULL
«	NULL
B	NULL
blocked	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
fasL-dependent	NULL
reporter	NULL
by	NULL
these	NULL
treatments	NULL
.	NULL

Some	NULL
correlative	NULL
evidence	NULL
has	NULL
suggested	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
also	NULL
has	NULL
a	NULL
role	NULL
in	NULL
TCR-induced	NULL
fasL	NULL
expression	NULL
.	NULL

For	NULL
example	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
,	NULL
which	NULL
is	NULL
increased	NULL
by	NULL
proteasome-mediated	NULL
degradation	NULL
of	NULL
its	NULL
cytoplasmic	NULL
inhibitor	NULL
I-	NULL
«	NULL
B	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
fasL	NULL
expression	NULL
are	NULL
both	NULL
blocked	NULL
by	NULL
proteasome	NULL
inhibitors	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
induction	NULL
of	NULL
both	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activity	NULL
and	NULL
fasL	NULL
transcription	NULL
by	NULL
TCR	NULL
signals	NULL
is	NULL
sensitive	NULL
to	NULL
antioxidants	NULL
,	NULL
and	NULL
pro-oxidants	NULL
such	NULL
as	NULL
hydrogen	NULL
peroxide	NULL
can	NULL
induce	NULL
both	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Both	NULL
activation-	NULL
and	NULL
perox-ide-induced	NULL
apoptosis	NULL
were	NULL
inhibited	NULL
by	NULL
overexpression	NULL
of	NULL
dominant	NULL
negative	NULL
I-xB	NULL
(	NULL
18	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
that	NULL
apparently	NULL
takes	NULL
part	NULL
in	NULL
stress-induced	NULL
faosL	NULL
up-regulation	NULL
lies	NULL
outside	NULL
of	NULL
the	NULL
region	NULL
that	NULL
confers	NULL
TCR	NULL
inducibility	NULL
of	NULL
fasL	NULL
transcription	NULL
,	NULL
and	NULL
a	NULL
potential	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
that	NULL
does	NULL
lie	NULL
in	NULL
this	NULL
region	NULL
(	NULL
19	NULL
)	NULL
is	NULL
dispensable	NULL
for	NULL
TCR-mediated	NULL
fasL	NULL
up-regulation	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

There	NULL
are	NULL
a	NULL
number	NULL
of	NULL
lines	NULL
of	NULL
evidence	NULL
to	NULL
suggest	NULL
that	NULL
NF-AT	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
fasL	NULL
up-regulation	NULL
.	NULL

First	NULL
,	NULL
fasL	NULL
induction	NULL
by	NULL
TCR-mediated	NULL
stimulation	NULL
is	NULL
sensitive	NULL
to	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
anti-TCR-induced	NULL
up-regulation	NULL
of	NULL
fasL	NULL
in	NULL
vivo	NULL
is	NULL
impaired	NULL
in	NULL
NF-ATp	NULL
knockout	NULL
mice	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Footprinting	NULL
analysis	NULL
of	NULL
the	NULL
fasL	NULL
promoter	NULL
with	NULL
the	NULL
use	NULL
of	NULL
recombinant	NULL
proteins	NULL
identified	NULL
two	NULL
potential	NULL
NF-AT-binding	NULL
sites	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
distal	NULL
site	NULL
,	NULL
located	NULL
at	NULL
-275	NULL
relative	NULL
to	NULL
the	NULL
coding	NULL
region	NULL
,	NULL
was	NULL
found	NULL
to	NULL
contribute	NULL
to	NULL
fasL	NULL
reporter	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
22	NULL
,	NULL
26	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
we	NULL
found	NULL
that	NULL
mutation	NULL
or	NULL
deletion	NULL
of	NULL
the	NULL
NF-AT	NULL
site	NULL
at	NULL
-275	NULL
did	NULL
not	NULL
have	NULL
a	NULL
substantial	NULL
effect	NULL
on	NULL
fasL	NULL
up-regulation	NULL
and	NULL
described	NULL
a	NULL
fasL	NULL
regulatory	NULL
element	NULL
(	NULL
FLRE	NULL
]	NULL
located	NULL
from	NULL
-214	NULL
to	NULL
-207	NULL
in	NULL
the	NULL
fasL	NULL
promoter	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
FLRE	NULL
conferred	NULL
the	NULL
majority	NULL
of	NULL
TCR-inducible	NULL
fasL	NULL
promoter	NULL
activity	NULL
in	NULL
a	NULL
murine	NULL
T	NULL
cell	NULL
hybridoma	NULL
and	NULL
in	NULL
human	NULL
T	NULL
cell	NULL
blasts	NULL
and	NULL
proved	NULL
to	NULL
be	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
Egr-1	NULL
and	NULL
Egr-3	NULL
,	NULL
members	NULL
of	NULL
the	NULL
Egr	NULL
(	NULL
early	NULL
growth	NULL
response	NULL
)	NULL
family	NULL
This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Role	NULL
of	NULL
Egr-2	NULL
in	NULL
Up-regulation	NULL
of	NULL
Fas	NULL
Ligand	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Overexpression	NULL
of	NULL
Egr-3	NULL
but	NULL
not	NULL
Egr-1	NULL
was	NULL
sufficient	NULL
to	NULL
induce	NULL
an	NULL
FLRE-dependent	NULL
reporter	NULL
construct	NULL
as	NULL
well	NULL
as	NULL
an	NULL
increase	NULL
in	NULL
cellular	NULL
fasL	NULL
mRNA	NULL
.	NULL

TCR-mediated	NULL
induction	NULL
of	NULL
Egr-3	NULL
but	NULL
not	NULL
Egr-1	NULL
was	NULL
sensitive	NULL
to	NULL
inhibition	NULL
by	NULL
CsA	NULL
,	NULL
suggesting	NULL
that	NULL
Egr-3	NULL
may	NULL
be	NULL
a	NULL
transcriptional	NULL
target	NULL
of	NULL
NF-AT	NULL
.	NULL

These	NULL
data	NULL
indicated	NULL
that	NULL
Egr-3	NULL
rather	NULL
than	NULL
the	NULL
more	NULL
abundant	NULL
Egr-1	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
direct	NULL
mediator	NULL
of	NULL
fasL	NULL
transcription	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Transcription	NULL
of	NULL
Egr	NULL
family	NULL
genes	NULL
is	NULL
up-regulated	NULL
after	NULL
TCR	NULL
activation	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

These	NULL
Zn**	NULL
finger-containing	NULL
proteins	NULL
have	NULL
similar	NULL
DNA-binding	NULL
domains	NULL
and	NULL
similar	NULL
DNA	NULL
sequence	NULL
preference	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Other	NULL
domains	NULL
of	NULL
the	NULL
proteins	NULL
differ	NULL
,	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
Egr	NULL
family	NULL
genes	NULL
can	NULL
be	NULL
differentially	NULL
regulated	NULL
,	NULL
suggesting	NULL
that	NULL
individual	NULL
members	NULL
fulfill	NULL
nonredundant	NULL
biological	NULL
roles	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
examine	NULL
MRL	NULL
and	NULL
C3H-gld/gld	NULL
DN	NULL
T	NULL
cells	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
FLRE-binding	NULL
proteins	NULL
that	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
constitutive	NULL
activation	NULL
of	NULL
the	NULL
fasL	NULL
promoter	NULL
.	NULL

The	NULL
results	NULL
indicate	NULL
that	NULL
Egr-2	NULL
,	NULL
like	NULL
Egr-3	NULL
,	NULL
can	NULL
directly	NULL
mediate	NULL
TCR-induced	NULL
transcription	NULL
of	NULL
fasL	NULL
,	NULL
and	NULL
it	NULL
is	NULL
this	NULL
member	NULL
of	NULL
the	NULL
Egr	NULL
family	NULL
that	NULL
appears	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
aberrant	NULL
up-regulation	NULL
of	NULL
this	NULL
gene	NULL
in	NULL
lpr	NULL
and	NULL
gld	NULL
mice	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Lines	NULL
,	NULL
Mice	NULL
,	NULL
and	NULL
Reagents-2B4.11	NULL
is	NULL
a	NULL
murine	NULL
T	NULL
cell	NULL
hybridoma	NULL
specific	NULL
for	NULL
peptide	NULL
81-104	NULL
of	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
presented	NULL
by	NULL
I-E*	NULL
(	NULL
81	NULL
)	NULL
and	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Biofluids	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
supplemented	NULL
with	NULL
4	NULL
mM	NULL
glutamine	NULL
,	NULL
50	NULL
uM	NULL
B-mercaptoethanol	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
150	NULL
pg/ml	NULL
gentamicin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
complete	NULL
medium	NULL
)	NULL
.	NULL

Hela	NULL
(	NULL
human	NULL
cervical	NULL
carcinoma	NULL
)	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
Biofluids	NULL
)	NULL
with	NULL
the	NULL
foregoing	NULL
supplements	NULL
.	NULL

CSH	NULL
(	NULL
10	NULL
weeks	NULL
of	NULL
age	NULL
)	NULL
,	NULL
and	NULL
C8H-gld/gld	NULL
MRL	NULL
Ipr/lipr	NULL
mice	NULL
(	NULL
4-5	NULL
months	NULL
of	NULL
age	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Jackson	NULL
Laboratories	NULL
(	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
interbred	NULL
(	NULL
C57BI/6	NULL
%	NULL
DBA2	NULL
)	NULL
F	NULL
,	NULL
mice	NULL
maintained	NULL
in	NULL
our	NULL
animal	NULL
facility	NULL
were	NULL
used	NULL
.	NULL

CsA	NULL
was	NULL
obtained	NULL
from	NULL
Sandoz	NULL
.	NULL

Protein	NULL
A-purified	NULL
antisera	NULL
against	NULL
Egr-1	NULL
,	NULL
Egr-3	NULL
,	NULL
WT-1	NULL
,	NULL
and	NULL
an	NULL
unknown	NULL
protein	NULL
(	NULL
anti-Eigr-2	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Technologies	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

An	NULL
antiserum	NULL
against	NULL
Egr-2	NULL
was	NULL
obtained	NULL
from	NULL
Berkeley	NULL
Antibody	NULL
(	NULL
Berkeley	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Plasmids-The	NULL
16-mer	NULL
plasmid	NULL
,	NULL
with	NULL
a	NULL
16-bp	NULL
FLRE-containing	NULL
element	NULL
(	NULL
from	NULL
-220	NULL
to	NULL
-205	NULL
,	NULL
relative	NULL
to	NULL
the	NULL
initiating	NULL
codon	NULL
)	NULL
appended	NULL
to	NULL
a	NULL
fasL	NULL
minimal	NULL
promoter	NULL
(	NULL
from	NULL
-187	NULL
to	NULL
-1	NULL
)	NULL
,	NULL
the	NULL
``	NULL
m16-mer	NULL
``	NULL
plasmid	NULL
,	NULL
in	NULL
which	NULL
a	NULL
4-bp	NULL
substitution	NULL
in	NULL
the	NULL
FLRE	NULL
(	NULL
-214	NULL
to	NULL
-211	NULL
:	NULL
GTGG	NULL
-	NULL
CACC	NULL
)	NULL
was	NULL
made	NULL
,	NULL
the	NULL
305-mer	NULL
,	NULL
the	NULL
225-mer	NULL
,	NULL
and	NULL
the	NULL
212-mer	NULL
plasmids	NULL
,	NULL
all	NULL
driving	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
of	NULL
the	NULL
vector	NULL
pGL8	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
were	NULL
described	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
plasmids	NULL
encoding	NULL
NGFI-A	NULL
(	NULL
Eigr-1	NULL
)	NULL
,	NULL
Egr-2	NULL
,	NULL
and	NULL
Egr-3	NULL
were	NULL
described	NULL
(	NULL
82	NULL
)	NULL
.	NULL

Transient	NULL
Transfection	NULL
Assays-In	NULL
cotransfection	NULL
experiments	NULL
,	NULL
a	NULL
Gene	NULL
Pulser	NULL
(	NULL
Bio-Rad	NULL
)	NULL
was	NULL
used	NULL
to	NULL
electroporate	NULL
2B4.11	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
in	NULL
0.2	NULL
ml	NULL
of	NULL
complete	NULL
medium	NULL
in	NULL
4-mm	NULL
cuvettes	NULL
,	NULL
with	NULL
7.5	NULL
ug	NULL
of	NULL
expression	NULL
plasmid	NULL
and	NULL
2.5	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
,	NULL
by	NULL
using	NULL
960	NULL
microfarads	NULL
at	NULL
220	NULL
V.	NULL
The	NULL
plasmid	NULL
pCB6	NULL
(	NULL
83	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
for	NULL
the	NULL
expression	NULL
plasmids	NULL
.	NULL

Each	NULL
transfection	NULL
was	NULL
cultured	NULL
in	NULL
1-ml	NULL
volumes	NULL
in	NULL
complete	NULL
medium	NULL
and	NULL
,	NULL
the	NULL
luciferase	NULL
activity	NULL
in	NULL
20	NULL
%	NULL
of	NULL
each	NULL
was	NULL
measured	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
the	NULL
standard	NULL
deviation	NULL
of	NULL
the	NULL
fold	NULL
inductions	NULL
(	NULL
Egr-expressing	NULL
plasmid	NULL
relative	NULL
to	NULL
empty	NULL
plasmid	NULL
)	NULL
of	NULL
duplicate	NULL
sam-ples	NULL
.	NULL

MRL-Ipr/ipr	NULL
lymph	NULL
node	NULL
cells	NULL
(	NULL
4	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
electroporated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
fasL-dependent	NULL
luciferase-encoding	NULL
reporter	NULL
plasmid	NULL
by	NULL
using	NULL
960	NULL
microfarads	NULL
at	NULL
250	NULL
V.	NULL
Each	NULL
transfection	NULL
was	NULL
cultured	NULL
in	NULL
4	NULL
ml	NULL
of	NULL
complete	NULL
medium	NULL
,	NULL
and	NULL
the	NULL
luciferase	NULL
activity	NULL
in	NULL
20	NULL
%	NULL
of	NULL
it	NULL
was	NULL
measured	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
the	NULL
standard	NULL
deviation	NULL
of	NULL
duplicate	NULL
transfections	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
(	NULL
34	NULL
)	NULL
.	NULL

In	NULL
reporter	NULL
assays	NULL
,	NULL
triplicate	NULL
200-4.l	NULL
cultures	NULL
were	NULL
transfected	NULL
with	NULL
150	NULL
ng	NULL
of	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
and	NULL
150	NULL
ng	NULL
of	NULL
expression	NULL
plasmid	NULL
,	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
luciferase	NULL
activity	NULL
in	NULL
40	NULL
%	NULL
of	NULL
each	NULL
culture	NULL
was	NULL
measured	NULL
.	NULL

In	NULL
RT-PCR	NULL
assays	NULL
,	NULL
4-ml	NULL
cultures	NULL
were	NULL
transfected	NULL
with	NULL
7.5	NULL
pug	NULL
of	NULL
expression	NULL
plasmid	NULL
,	NULL
and	NULL
20	NULL
%	NULL
of	NULL
the	NULL
resulting	NULL
RNA	NULL
was	NULL
used	NULL
for	NULL
synthesis	NULL
of	NULL
cDNA	NULL
.	NULL

Gel	NULL
Shift	NULL
Assays-Whole	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
resuspending	NULL
phosphate-buffered	NULL
saline-washed	NULL
cells	NULL
in	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
400	NULL
mM	NULL
KCl	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenyImethylsul-fonyl	NULL
fluoride	NULL
and	NULL
subjecting	NULL
them	NULL
to	NULL
three	NULL
rounds	NULL
of	NULL
freezing	NULL
on	NULL
dry	NULL
ice	NULL
followed	NULL
by	NULL
rapid	NULL
thawing	NULL
in	NULL
a	NULL
87	NULL
°C	NULL
water	NULL
bath	NULL
.	NULL

Extracts	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
supernatants	NULL
after	NULL
5	NULL
min	NULL
of	NULL
centrifugation	NULL
at	NULL
14,000	NULL
X	NULL
g	NULL
at	NULL
4°C	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
22	NULL
°C	NULL
for	NULL
80	NULL
min	NULL
by	NULL
com	NULL
3223	NULL
bining	NULL
extracts	NULL
with	NULL
12	NULL
pl	NULL
of	NULL
binding	NULL
buffer	NULL
(	NULL
10	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
)	NULL
containing	NULL
1	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
0.02	NULL
pmol	NULL
of	NULL
°P	NULL
end-labeled	NULL
double-stranded	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

In	NULL
antibody	NULL
supershift	NULL
assays	NULL
,	NULL
1-2	NULL
pul	NULL
(	NULL
1-2	NULL
ug	NULL
)	NULL
of	NULL
total	NULL
antiserum	NULL
or	NULL
phosphate-buffered	NULL
saline	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

Complexes	NULL
and	NULL
unbound	NULL
probe	NULL
were	NULL
separated	NULL
on	NULL
4.5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
with	NULL
the	NULL
use	NULL
of	NULL
0.5	NULL
X	NULL
TBE	NULL
running	NULL
buffer	NULL
.	NULL

Northern	NULL
Blot	NULL
Analysis-Total	NULL
RNA	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
isolated	NULL
using	NULL
the	NULL
Trizol	NULL
denaturant	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
was	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
a	NULL
1.5	NULL
%	NULL
agarose	NULL
gel	NULL
containing	NULL
6	NULL
%	NULL
formaldehyde	NULL
and	NULL
buffered	NULL
with	NULL
MOPS	NULL
(	NULL
Quality	NULL
Biological	NULL
,	NULL
Inc.	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

After	NULL
transfer	NULL
to	NULL
a	NULL
HyBond-N	NULL
membrane	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
,	NULL
RNA	NULL
was	NULL
covalently	NULL
bound	NULL
by	NULL
UV	NULL
cross-linking	NULL
.	NULL

Hybridization	NULL
with	NULL
°°P-labeled	NULL
cDNA	NULL
probes	NULL
was	NULL
carried	NULL
out	NULL
at	NULL
65	NULL
°C	NULL
in	NULL
0.5	NULL
M	NULL
sodium	NULL
,	NULL
7	NULL
%	NULL
SDS	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
and	NULL
buffered	NULL
to	NULL
pH	NULL
7.2	NULL
with	NULL
phosphate	NULL
(	NULL
85	NULL
)	NULL
.	NULL

The	NULL
cDNAs	NULL
encoding	NULL
the	NULL
extracellular	NULL
part	NULL
of	NULL
mouse	NULL
FasL	NULL
and	NULL
the	NULL
Pst-1	NULL
fragment	NULL
of	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
(	NULL
86	NULL
)	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
.	NULL

Final	NULL
washes	NULL
were	NULL
performed	NULL
at	NULL
60	NULL
°C	NULL
in	NULL
80	NULL
mM	NULL
sodium	NULL
,	NULL
phosphate-buffered	NULL
as	NULL
before	NULL
,	NULL
with	NULL
1	NULL
%	NULL
SDS	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
.	NULL

After	NULL
exposure	NULL
to	NULL
detect	NULL
fasL	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
stripped	NULL
by	NULL
boiling	NULL
in	NULL
0.1	NULL
%	NULL
SSC	NULL
and	NULL
1	NULL
%	NULL
SDS	NULL
and	NULL
probed	NULL
for	NULL
gapdh	NULL
.	NULL

RT-PCR-cDNA	NULL
was	NULL
synthesized	NULL
with	NULL
the	NULL
use	NULL
of	NULL
random	NULL
hexamers	NULL
and	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
(	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
PCR	NULL
primers	NULL
,	NULL
which	NULL
were	NULL
designed	NULL
to	NULL
amplify	NULL
eDNA	NULL
and	NULL
not	NULL
genomic	NULL
DNA	NULL
,	NULL
were	NULL
:	NULL
human	NULL
fasL	NULL
,	NULL
ATGTTTCAGCTCTTCCAC-CTACAGA	NULL
(	NULL
forward	NULL
)	NULL
and	NULL
CCAGAGAGAGCTCAGATACGTTGACA	NULL
(	NULL
re-verse	NULL
)	NULL
,	NULL
and	NULL
human	NULL
gapdh	NULL
,	NULL
AGGTCGGAGTCAACGGATTT	NULL
(	NULL
forward	NULL
)	NULL
and	NULL
CAGCAGAGGGGGCAGAGATG	NULL
(	NULL
reverse	NULL
)	NULL
.	NULL

1	NULL
ul	NULL
of	NULL
cDNA	NULL
was	NULL
amplified	NULL
in	NULL
a	NULL
25-ul	NULL
PCR	NULL
reaction	NULL
with	NULL
the	NULL
use	NULL
of	NULL
``	NULL
Ready	NULL
To	NULL
Go	NULL
``	NULL
PCR	NULL
beads	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
with	NULL
MgCl	NULL
,	NULL
supplemented	NULL
to	NULL
2	NULL
mM	NULL
.	NULL

Products	NULL
derived	NULL
from	NULL
40	NULL
amplification	NULL
cycles	NULL
of	NULL
1	NULL
min	NULL
at	NULL
95	NULL
°C	NULL
,	NULL
1	NULL
min	NULL
at	NULL
62	NULL
°C	NULL
,	NULL
and	NULL
1	NULL
min	NULL
at	NULL
72	NULL
°C	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
a	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
HyBond-N	NULL
membrane	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
probed	NULL
with	NULL
the	NULL
``	NULL
°P-labeled	NULL
human	NULL
fasL	NULL
cDNA	NULL
.	NULL

To	NULL
control	NULL
for	NULL
the	NULL
integrity	NULL
and	NULL
uniformity	NULL
of	NULL
the	NULL
sample	NULL
preparations	NULL
,	NULL
gapdh	NULL
was	NULL
amplified	NULL
with	NULL
25	NULL
cycles	NULL
of	NULL
1	NULL
min	NULL
at	NULL
95	NULL
°C	NULL
,	NULL
1	NULL
min	NULL
at	NULL
55	NULL
°C	NULL
,	NULL
and	NULL
1	NULL
min	NULL
at	NULL
72	NULL
°C	NULL
,	NULL
and	NULL
the	NULL
products	NULL
were	NULL
transferred	NULL
and	NULL
probed	NULL
as	NULL
before	NULL
.	NULL

RESULTS	NULL
lpr	NULL
and	NULL
gid	NULL
Lymph	NULL
Node	NULL
T	NULL
Cells	NULL
Contain	NULL
Elevated	NULL
Levels	NULL
of	NULL
the	NULL
FLRE-binding	NULL
Proteins	NULL
Egr-1	NULL
and	NULL
Egr-2-Mice	NULL
of	NULL
the	NULL
CBH-gid	NULL
/gld	NULL
(	NULL
gld	NULL
)	NULL
and	NULL
MRL-Ipr/lpr	NULL
(	NULL
Ipr	NULL
)	NULL
background	NULL
acquire	NULL
massive	NULL
numbers	NULL
of	NULL
CD4	NULL
~CD8~	NULL
T	NULL
cells	NULL
that	NULL
bear	NULL
characteristics	NULL
indicative	NULL
of	NULL
chronic	NULL
activation	NULL
and	NULL
express	NULL
constitutively	NULL
elevated	NULL
levels	NULL
of	NULL
fasL	NULL
mRNA	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Because	NULL
we	NULL
have	NULL
recently	NULL
found	NULL
that	NULL
the	NULL
fasL	NULL
promoter	NULL
is	NULL
under	NULL
the	NULL
direct	NULL
control	NULL
of	NULL
the	NULL
activation-inducible	NULL
and	NULL
CsA-sensitive	NULL
transcription	NULL
factor	NULL
Egr-3	NULL
(	NULL
20	NULL
)	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
T	NULL
cells	NULL
from	NULL
lpr	NULL
and	NULL
gld	NULL
mice	NULL
contain	NULL
elevated	NULL
levels	NULL
of	NULL
FLRE-binding	NULL
proteins	NULL
.	NULL

Extracts	NULL
derived	NULL
from	NULL
freshly	NULL
isolated	NULL
lymph	NULL
nodes	NULL
from	NULL
3-5-month-old	NULL
lpr	NULL
and	NULL
gld	NULL
mice	NULL
,	NULL
which	NULL
consist	NULL
almost	NULL
entirely	NULL
of	NULL
DN	NULL
T	NULL
cells	NULL
(	NULL
Ref	NULL
.	NULL

37	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
were	NULL
examined	NULL
by	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
gel	NULL
shift	NULL
)	NULL
.	NULL

Incubating	NULL
extracts	NULL
from	NULL
either	NULL
mouse	NULL
with	NULL
the	NULL
labeled	NULL
FLRE	NULL
revealed	NULL
a	NULL
major	NULL
retarded	NULL
species	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
bands	NULL
I	NULL
and	NULL
IT	NULL
)	NULL
.	NULL

The	NULL
center	NULL
of	NULL
migration	NULL
of	NULL
this	NULL
band	NULL
was	NULL
slightly	NULL
faster	NULL
than	NULL
that	NULL
of	NULL
a	NULL
band	NULL
previously	NULL
identified	NULL
as	NULL
Egr-1	NULL
in	NULL
activated	NULL
2B4.11	NULL
T	NULL
hybridoma	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
stimulated	NULL
2B4.11	NULL
cells	NULL
)	NULL
and	NULL
corresponded	NULL
to	NULL
the	NULL
migration	NULL
of	NULL
Egr-1	NULL
and	NULL
Egr-2	NULL
generated	NULL
by	NULL
transient	NULL
expression	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
a	NULL
nonspecific	NULL
antiserum	NULL
or	NULL
an	NULL
antiserum	NULL
specific	NULL
for	NULL
the	NULL
distantly	NULL
related	NULL
Egr	NULL
family	NULL
member	NULL
WT-1	NULL
,	NULL
the	NULL
product	NULL
of	NULL
the	NULL
Wilms	NULL
'	NULL
tumor	NULL
suppressor	NULL
gene	NULL
locus	NULL
,	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
gel	NULL
shift	NULL
patterns	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
antisera	NULL
specific	NULL
for	NULL
Egr-1	NULL
caused	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
major	NULL
shifted	NULL
band	NULL
I	NULL
,	NULL
and	NULL
the	NULL
remaining	NULL
material	NULL
(	NULL
band	NULL
II	NULL
)	NULL
migrated	NULL
slightly	NULL
more	NULL
rapidly	NULL
than	NULL
the	NULL
mean	NULL
of	NULL
bands	NULL
I	NULL
and	NULL
II	NULL
.	NULL

The	NULL
anti-Egr-1	NULL
antibodies	NULL
also	NULL
caused	NULL
the	NULL
appearance	NULL
of	NULL
supershifted	NULL
anti-body-antigen-DNA	NULL
complexes	NULL
of	NULL
slower	NULL
mobility	NULL
.	NULL

Antibodies	NULL
against	NULL
Egr-2	NULL
also	NULL
reduced	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
principal	NULL
band	NULL
;	NULL
in	NULL
this	NULL
case	NULL
the	NULL
remaining	NULL
material	NULL
(	NULL
band	NULL
I	NULL
)	NULL
migrated	NULL
more	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
3224	NULL
gld	NULL
Role	NULL
of	NULL
Egr-2	NULL
in	NULL
Up-regulation	NULL
of	NULL
Fas	NULL
Ligand	NULL
Stimulated	NULL
Ipr	NULL
2B4.11	NULL
Antisera	NULL
added	NULL
:	NULL
Egr-3	NULL
Wit	NULL
»	NULL
Egr-1	NULL
&	NULL
-2	NULL
None	NULL
-	NULL
Egr-1	NULL
Ub	NULL
Egr-2	NULL
WT	NULL
NS	NULL
i=	NULL
t	NULL
,	NULL
,	NULL
WW	NULL
i=	NULL
tw	NULL
=	NULL
Wit	NULL
W	NULL
rv	NULL
-	NULL
t	NULL
las	NULL
lat	NULL
tas	NULL
tant	NULL
bath	NULL
tat	NULL
Ul	NULL
Egr-1	NULL
&	NULL
-2	NULL
None	NULL
Egr-1	NULL
©	NULL
Egr-2	NULL
Egr-3	NULL
U	NULL
Egr-1	NULL
&	NULL
-2	NULL
WT	NULL
NS	NULL
None	NULL
UB	NULL
Egr-1	NULL
&	NULL
-3	NULL
J	NULL
mat	NULL
tat	NULL
wat	NULL
was	NULL
tat	NULL
tas	NULL
wis	NULL
Sth	NULL
linus	NULL
(	NULL
s	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Analysis	NULL
of	NULL
FLRE-binding	NULL
proteins	NULL
in	NULL
Ipr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
cell	NULL
extracts	NULL
.	NULL

Extracts	NULL
of	NULL
freshly	NULL
isolated	NULL
and	NULL
untreated	NULL
lpr	NULL
and	NULL
gld	NULL
lymph	NULL
node	NULL
DN	NULL
T	NULL
cells	NULL
or	NULL
2B4.11	NULL
cells	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
ionomycin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
end-labeled	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
region	NULL
from	NULL
-220	NULL
to	NULL
-205	NULL
(	NULL
16-mer	NULL
)	NULL
of	NULL
the	NULL
fasL	NULL
promoter	NULL
.	NULL

Complexes	NULL
were	NULL
resolved	NULL
by	NULL
electrophoresis	NULL
on	NULL
5	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Antisera	NULL
raised	NULL
against	NULL
the	NULL
indicated	NULL
molecules	NULL
were	NULL
added	NULL
during	NULL
the	NULL
incubation	NULL
.	NULL

Bands	NULL
corresponding	NULL
to	NULL
Egr-1	NULL
(	NULL
band	NULL
D	NULL
)	NULL
,	NULL
Egr-2	NULL
(	NULL
band	NULL
II	NULL
)	NULL
,	NULL
Egr-3	NULL
(	NULL
band	NULL
III	NULL
)	NULL
,	NULL
and	NULL
a	NULL
nonspecific	NULL
(	NULL
NS	NULL
)	NULL
band	NULL
(	NULL
band	NULL
IV	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
mobility	NULL
of	NULL
these	NULL
species	NULL
correlated	NULL
with	NULL
that	NULL
of	NULL
the	NULL
homologous	NULL
rat	NULL
proteins	NULL
expressed	NULL
in	NULL
Hela	NULL
cells	NULL
by	NULL
transient	NULL
transfection	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

WT	NULL
,	NULL
Wilms	NULL
'	NULL
tumor	NULL
antigen	NULL
WT-L.	NULL
slowly	NULL
than	NULL
the	NULL
combined	NULL
bands	NULL
I	NULL
and	NULL
II	NULL
.	NULL

Anti-Egr-2	NULL
caused	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
supershifted	NULL
complex	NULL
of	NULL
mobility	NULL
different	NULL
from	NULL
that	NULL
of	NULL
the	NULL
Egr-1	NULL
supershifted	NULL
complex	NULL
.	NULL

Simultaneous	NULL
addition	NULL
of	NULL
both	NULL
Egr-1	NULL
and	NULL
Egr-2-specific	NULL
antisera	NULL
caused	NULL
the	NULL
complete	NULL
disappearance	NULL
of	NULL
the	NULL
major	NULL
retarded	NULL
species	NULL
.	NULL

Only	NULL
a	NULL
very	NULL
small	NULL
amount	NULL
of	NULL
material	NULL
migrated	NULL
more	NULL
rapidly	NULL
than	NULL
band	NULL
II	NULL
,	NULL
and	NULL
,	NULL
unlike	NULL
activated	NULL
2B4.11	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
Ref	NULL
.	NULL

20	NULL
)	NULL
,	NULL
antisera	NULL
against	NULL
Egr-3	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
this	NULL
band	NULL
III	NULL
in	NULL
lpr	NULL
and	NULL
gld	NULL
cell	NULL
extracts	NULL
.	NULL

Finally	NULL
,	NULL
as	NULL
with	NULL
2B4.11	NULL
cells	NULL
,	NULL
band	NULL
IV	NULL
is	NULL
constitutively	NULL
present	NULL
and	NULL
is	NULL
not	NULL
eliminated	NULL
by	NULL
the	NULL
unlabeled	NULL
FLRE	NULL
oligonucleotide	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
unstimulated	NULL
DN	NULL
T	NULL
cells	NULL
from	NULL
both	NULL
lpr	NULL
and	NULL
gld	NULL
mice	NULL
have	NULL
little	NULL
if	NULL
any	NULL
Egr-3	NULL
but	NULL
,	NULL
unlike	NULL
normal	NULL
unac-tivated	NULL
T	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
,	NULL
constitutively	NULL
express	NULL
Egr-1	NULL
and	NULL
Egr-2	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
binding	NULL
to	NULL
the	NULL
FLRE	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
different	NULL
Egr	NULL
family	NULL
transcription	NULL
factors	NULL
in	NULL
DN	NULL
T	NULL
cells	NULL
was	NULL
further	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

RNA	NULL
from	NULL
freshly	NULL
isolated	NULL
lpr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
cells	NULL
had	NULL
elevated	NULL
levels	NULL
of	NULL
egr-1	NULL
and	NULL
egr-2	NULL
when	NULL
compared	NULL
with	NULL
unacti-vated	NULL
normal	NULL
C3H	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
level	NULL
of	NULL
egr-3	NULL
in	NULL
DN	NULL
T	NULL
cells	NULL
was	NULL
,	NULL
although	NULL
slightly	NULL
higher	NULL
than	NULL
that	NULL
in	NULL
unstimulated	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
substantially	NULL
lower	NULL
than	NULL
that	NULL
in	NULL
activated	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
lpr	NULL
and	NULL
gld	NULL
lymph	NULL
node	NULL
DN	NULL
T	NULL
cells	NULL
have	NULL
an	NULL
activated	NULL
phenotype	NULL
with	NULL
regard	NULL
to	NULL
Egr	NULL
family	NULL
protein	NULL
expression	NULL
,	NULL
with	NULL
constitutively	NULL
high	NULL
levels	NULL
of	NULL
Egr-1	NULL
and	NULL
Egr-2	NULL
and	NULL
relatively	NULL
little	NULL
Eigr-3	NULL
.	NULL

Egr-2	NULL
Is	NULL
Among	NULL
the	NULL
Induced	NULL
FLRE-binding	NULL
Proteins	NULL
in	NULL
Activated	NULL
2B4.11	NULL
and	NULL
Normal	NULL
T	NULL
Cells-The	NULL
expression	NULL
of	NULL
Egr-2	NULL
in	NULL
a	NULL
T	NULL
hybridoma	NULL
cell	NULL
line	NULL
and	NULL
normal	NULL
T	NULL
cells	NULL
was	NULL
examined	NULL
.	NULL

Egr-2	NULL
,	NULL
whose	NULL
migration	NULL
is	NULL
only	NULL
slightly	NULL
faster	NULL
than	NULL
Egr-1	NULL
,	NULL
was	NULL
not	NULL
previously	NULL
recognized	NULL
by	NULL
gel	NULL
shift	NULL
analysis	NULL
in	NULL
extracts	NULL
of	NULL
activated	NULL
2B4.11	NULL
T	NULL
hybridoma	NULL
cells	NULL
,	NULL
and	NULL
no	NULL
supershifted	NULL
material	NULL
was	NULL
detected	NULL
with	NULL
a	NULL
commercially	NULL
available	NULL
putative	NULL
anti-Egr-2	NULL
polyclonal	NULL
antiserum	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Reexamination	NULL
of	NULL
cell	NULL
extracts	NULL
from	NULL
activated	NULL
2B4.11	NULL
cells	NULL
revealed	NULL
,	NULL
however	NULL
,	NULL
that	NULL
supershifting	NULL
with	NULL
anti-Egr-1	NULL
and	NULL
anti-Egr-3	NULL
antibodies	NULL
left	NULL
a	NULL
faint	NULL
band	NULL
that	NULL
migrated	NULL
slightly	NULL
faster	NULL
than	NULL
the	NULL
bulk	NULL
of	NULL
the	NULL
Egr-1	NULL
material	NULL
and	NULL
co-migrated	NULL
with	NULL
recombinant	NULL
Egr-2	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
addition	NULL
of	NULL
a	NULL
different	NULL
anti-Egr-2	NULL
antiserum	NULL
,	NULL
which	NULL
we	NULL
have	NULL
found	NULL
supershifts	NULL
recombinant	NULL
Egr-2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
removed	NULL
this	NULL
band	NULL
entirely	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
FLRE	NULL
binding	NULL
activity	NULL
in	NULL
activated	NULL
2B4.11	NULL
cells	NULL
consists	NULL
of	NULL
Egr-1	NULL
,	NULL
Egr-2	NULL
,	NULL
and	NULL
Egr-3	NULL
.	NULL

To	NULL
determine	NULL
what	NULL
FLRE-binding	NULL
proteins	NULL
are	NULL
induced	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
C3H	NULL
lymph	NULL
node	NULL
cells	NULL
were	NULL
studied	NULL
.	NULL

Small	NULL
amounts	NULL
of	NULL
shifted	NULL
material	NULL
in	NULL
the	NULL
region	NULL
corresponding	NULL
to	NULL
bands	NULL
I	NULL
,	NULL
II	NULL
,	NULL
and	NULL
III	NULL
could	NULL
be	NULL
seen	NULL
in	NULL
untreated	NULL
lymph	NULL
node	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

All	NULL
of	NULL
these	NULL
bands	NULL
,	NULL
in	NULL
particular	NULL
the	NULL
slower	NULL
species	NULL
corresponding	NULL
to	NULL
bands	NULL
Mouse	NULL
strain	NULL
:	NULL
-	NULL
C3H	NULL
lpr	NULL
gld	NULL
--	NULL
-	NULL
Treatment	NULL
:	NULL
-	NULL
P+I	NULL
-	NULL
egr-1	NULL
-	NULL
Ue	NULL
w=	NULL
a	NULL
»	NULL
egr-2	NULL
-	NULL
&	NULL
ain	NULL
an	NULL
egr-3	NULL
-	NULL
.	NULL

gapdh	NULL
-	NULL
%	NULL
o	NULL
¥	NULL
»	NULL
#	NULL
B	NULL
Wh	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Expression	NULL
of	NULL
Egr	NULL
family	NULL
mRNA	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
and	NULL
in	NULL
lpr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
cells	NULL
.	NULL

Northern	NULL
blots	NULL
were	NULL
prepared	NULL
with	NULL
RNA	NULL
from	NULL
freshly	NULL
isolated	NULL
lpr	NULL
and	NULL
gild	NULL
DN	NULL
T	NULL
cells	NULL
and	NULL
from	NULL
CSH	NULL
lymph	NULL
node	NULL
cells	NULL
that	NULL
were	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Individual	NULL
blots	NULL
prepared	NULL
from	NULL
the	NULL
same	NULL
set	NULL
of	NULL
RNA	NULL
samples	NULL
were	NULL
probed	NULL
with	NULL
the	NULL
indicated	NULL
*°P-labeled	NULL
cDNAs	NULL
.	NULL

P+I	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

``	NULL
9	NULL
o	NULL
Antisera	NULL
-	NULL
g	NULL
g	NULL
T	NULL
9	NULL
T	NULL
7	NULL
;	NULL
&	NULL
&	NULL
added	NULL
:	NULL
2	NULL
i	NULL
I	NULL
2	NULL
E	NULL
|	NULL
PMA	NULL
and	NULL
_|	NULL
;	NULL
p	NULL
p	NULL
q	NULL
4	NULL
ionomycin	NULL
:	NULL
{	NULL
-	NULL
-	NULL
MaWn	NULL
i	NULL
IH	NULL
IV	NULL
-	NULL
ms	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Analysis	NULL
of	NULL
FLRE-binding	NULL
proteins	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

Extracts	NULL
of	NULL
C3H	NULL
lymph	NULL
node	NULL
cells	NULL
that	NULL
were	NULL
either	NULL
freshly	NULL
isolated	NULL
or	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
were	NULL
analyzed	NULL
by	NULL
gel	NULL
shift	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

I	NULL
and	NULL
II	NULL
,	NULL
were	NULL
increased	NULL
in	NULL
cells	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Antisera	NULL
against	NULL
Egr-1	NULL
removed	NULL
most	NULL
,	NULL
but	NULL
not	NULL
all	NULL
,	NULL
of	NULL
the	NULL
more	NULL
slowly	NULL
migrating	NULL
species	NULL
and	NULL
caused	NULL
the	NULL
appearance	NULL
of	NULL
supershifted	NULL
material	NULL
,	NULL
and	NULL
antisera	NULL
against	NULL
Egr-2	NULL
removed	NULL
a	NULL
part	NULL
of	NULL
the	NULL
more	NULL
slowly	NULL
migrating	NULL
species	NULL
and	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Role	NULL
of	NULL
Egr-2	NULL
in	NULL
Up-regulation	NULL
of	NULL
Fas	NULL
Ligand	NULL
3225	NULL
*	NULL
j	NULL
Unstim	NULL
.	NULL
'	NULL

|	NULL
Fresh	NULL
+	NULL
}	NULL
P+I	NULL
CsA	NULL
:	NULL
egr-2	NULL
-	NULL
«	NULL
wan	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Egr-2	NULL
mRNA	NULL
induction	NULL
in	NULL
activated	NULL
normal	NULL
T	NULL
cells	NULL
is	NULL
sensitive	NULL
to	NULL
CsA	NULL
.	NULL

Total	NULL
RNA	NULL
from	NULL
(	NULL
C57BI/6	NULL
X	NULL
DBA2Z	NULL
)	NULL
F	NULL
,	NULL
mice	NULL
either	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
100	NULL
ng/ml	NULL
CsA	NULL
was	NULL
subjected	NULL
to	NULL
Northern	NULL
blot	NULL
analysis	NULL
for	NULL
egr-2	NULL
mRNA	NULL
expression	NULL
.	NULL

PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

caused	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
correspondingly	NULL
smaller	NULL
amount	NULL
of	NULL
supershifted	NULL
material	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
antisera	NULL
completely	NULL
removed	NULL
bands	NULL
I	NULL
and	NULL
II	NULL
.	NULL

As	NULL
with	NULL
2B4.11	NULL
cells	NULL
,	NULL
an	NULL
antiserum	NULL
against	NULL
Egr-3	NULL
specifically	NULL
removed	NULL
band	NULL
III	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
gel	NULL
shift	NULL
data	NULL
,	NULL
Northern	NULL
blot	NULL
analysis	NULL
demonstrated	NULL
that	NULL
mRNA	NULL
for	NULL
all	NULL
three	NULL
Egr	NULL
family	NULL
members	NULL
was	NULL
induced	NULL
by	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
normal	NULL
lymph	NULL
node	NULL
T	NULL
cells	NULL
,	NULL
activation	NULL
induces	NULL
the	NULL
appearance	NULL
of	NULL
Egr-1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
.	NULL

TCR-mediated	NULL
Egr-2	NULL
Induction	NULL
Is	NULL
Sensitive	NULL
to	NULL
CsA-TCR-mediated	NULL
induction	NULL
of	NULL
FasL	NULL
expression	NULL
is	NULL
inhibited	NULL
by	NULL
CsA	NULL
,	NULL
which	NULL
blocks	NULL
activation	NULL
of	NULL
the	NULL
NF-AT	NULL
transcription	NULL
factor	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
inhibiting	NULL
the	NULL
phosphatase	NULL
calcineurin	NULL
(	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
activation-induced	NULL
activity	NULL
of	NULL
the	NULL
FLRE	NULL
reporter	NULL
and	NULL
induction	NULL
of	NULL
Egr-3	NULL
,	NULL
but	NULL
not	NULL
Egr-1	NULL
,	NULL
are	NULL
sensitive	NULL
to	NULL
CsA	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
issue	NULL
of	NULL
whether	NULL
induced	NULL
Egr-2	NULL
expression	NULL
is	NULL
sensitive	NULL
to	NULL
inhibition	NULL
by	NULL
CsA	NULL
is	NULL
controversial	NULL
.	NULL

In	NULL
one	NULL
study	NULL
with	NULL
peripheral	NULL
blood	NULL
cells	NULL
(	NULL
28	NULL
)	NULL
,	NULL
CsA	NULL
was	NULL
found	NULL
to	NULL
have	NULL
a	NULL
relatively	NULL
small	NULL
effect	NULL
on	NULL
egr-2	NULL
induction	NULL
,	NULL
whereas	NULL
in	NULL
another	NULL
study	NULL
on	NULL
a	NULL
thymocyte	NULL
cell	NULL
line	NULL
,	NULL
CsA	NULL
was	NULL
found	NULL
to	NULL
inhibit	NULL
activation-induced	NULL
egr-2	NULL
(	NULL
40	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
Egr-2	NULL
induction	NULL
in	NULL
normal	NULL
murine	NULL
T	NULL
cells	NULL
is	NULL
CsA-sensitive	NULL
,	NULL
normal	NULL
lymph	NULL
node	NULL
cells	NULL
were	NULL
activated	NULL
by	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Egr-2	NULL
mRNA	NULL
levels	NULL
were	NULL
substantially	NULL
increased	NULL
by	NULL
activa-tion	NULL
,	NULL
a	NULL
response	NULL
that	NULL
was	NULL
inhibited	NULL
by	NULL
CsA	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
Egr-2	NULL
,	NULL
like	NULL
Egr-3	NULL
(	NULL
20	NULL
)	NULL
,	NULL
is	NULL
a	NULL
CsA-sensitive	NULL
T	NULL
cell	NULL
activation-inducible	NULL
transcription	NULL
factor	NULL
.	NULL

Egr-2	NULL
Expression	NULL
Is	NULL
Sufficient	NULL
to	NULL
Induce	NULL
fasL	NULL
Transcription-Egr	NULL
family	NULL
transcription	NULL
factors	NULL
contain	NULL
no	NULL
known	NULL
dimerization	NULL
domains	NULL
,	NULL
and	NULL
their	NULL
genetic	NULL
target	NULL
sites	NULL
are	NULL
asymmetrical	NULL
.	NULL

Therefore	NULL
,	NULL
they	NULL
are	NULL
thought	NULL
to	NULL
bind	NULL
to	NULL
DNA	NULL
and	NULL
activate	NULL
transcription	NULL
as	NULL
monomers	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
their	NULL
transcriptional	NULL
activity	NULL
is	NULL
not	NULL
thought	NULL
to	NULL
depend	NULL
on	NULL
post-translational	NULL
modification	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
transient	NULL
overexpression	NULL
of	NULL
Egr-3	NULL
was	NULL
previously	NULL
found	NULL
to	NULL
be	NULL
sufficient	NULL
for	NULL
induction	NULL
of	NULL
a	NULL
fasL	NULL
promoter	NULL
reporter	NULL
plasmid	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
TCR-mediated	NULL
activation	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Egr-2	NULL
was	NULL
likewise	NULL
tested	NULL
for	NULL
its	NULL
ability	NULL
to	NULL
independently	NULL
induce	NULL
fasL-specific	NULL
transcription	NULL
.	NULL

2B4.11	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
reporter	NULL
construct	NULL
encoding	NULL
the	NULL
luciferase	NULL
gene	NULL
driven	NULL
by	NULL
a	NULL
minimal	NULL
fasL	NULL
promoter	NULL
to	NULL
which	NULL
was	NULL
appended	NULL
the	NULL
region	NULL
from	NULL
-220	NULL
to	NULL
-205	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
FLRE	NULL
.	NULL

Enforced	NULL
expression	NULL
of	NULL
Egr-1	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
intact	NULL
reporter	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
shown	NULL
(	NULL
20	NULL
)	NULL
,	NULL
the	NULL
Egr-3	NULL
expression	NULL
plasmid	NULL
induced	NULL
significantly	NULL
higher	NULL
activity	NULL
.	NULL

Overexpression	NULL
of	NULL
Egr-2	NULL
resulted	NULL
in	NULL
a	NULL
response	NULL
that	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
induced	NULL
by	NULL
Egr-3	NULL
.	NULL

Cotransfection	NULL
of	NULL
plasmids	NULL
encoding	NULL
the	NULL
Egr	NULL
family	NULL
gene	NULL
products	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
reporter	NULL
construct	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
FLRE	NULL
that	NULL
eliminated	NULL
TCR-induced	NULL
activity	NULL
of	NULL
fasL	NULL
reporter	NULL
constructs	NULL
(	NULL
20	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
Egr-2	NULL
activates	NULL
the	NULL
FLRE	NULL
in	NULL
a	NULL
nonlymphoid	NULL
cell	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
its	NULL
overexpression	NULL
was	NULL
tested	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

As	NULL
with	NULL
the	NULL
2B4.11	NULL
cells	NULL
,	NULL
the	NULL
mutated	NULL
reporter	NULL
was	NULL
only	NULL
minimally	NULL
affected	NULL
by	NULL
cotransfected	NULL
Egr-expressing	NULL
plasmids	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
although	NULL
the	NULL
reporter	NULL
bearing	NULL
A	NULL
2B4.11	NULL
H	NULL
l6omer	NULL
O	NULL
mlémer	NULL
egr-1	NULL
egr-2	NULL
egr-3	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
HeLa	NULL
egr-1	NULL
egr-2	NULL
egr-3	NULL
1	NULL
20	NULL
40	NULL
60	NULL
80	NULL
100	NULL
120	NULL
Fold	NULL
induction	NULL
Vector	NULL
Egr-3	NULL
-RT	NULL
Egr-1	NULL
Egr-2	NULL
Egr-3	NULL
-fasl	NULL
«	NULL
woe	NULL
mme	NULL
canne	NULL
(	NULL
n	NULL
-gapdh	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Induction	NULL
of	NULL
fasL-dependent	NULL
transcription	NULL
by	NULL
transient	NULL
overexpression	NULL
of	NULL
Egr	NULL
family	NULL
members	NULL
.	NULL

A	NULL
,	NULL
2B4.11	NULL
or	NULL
Helia	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
Egr	NULL
family	NULL
expression	NULL
plasmids	NULL
and	NULL
luciferase	NULL
reporter	NULL
plasmids	NULL
that	NULL
were	NULL
dependent	NULL
on	NULL
either	NULL
a	NULL
wild	NULL
type	NULL
or	NULL
a	NULL
mutated	NULL
FLRE	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
14	NULL
h	NULL
(	NULL
2B4.11	NULL
)	NULL
or	NULL
32	NULL
h	NULL
(	NULL
HeLa	NULL
)	NULL
later	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
inductions	NULL
by	NULL
Egr	NULL
protein-expressing	NULL
plasmids	NULL
relative	NULL
to	NULL
the	NULL
empty	NULL
parental	NULL
plasmid	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
the	NULL
geometric	NULL
means	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
for	NULL
each	NULL
cell	NULL
type	NULL
.	NULL

B	NULL
,	NULL
Hela	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
Egr	NULL
family	NULL
expression	NULL
plasmids	NULL
,	NULL
and	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
human	NULL
fasL	NULL
mRNA	NULL
were	NULL
determined	NULL
by	NULL
RT-PCR	NULL
and	NULL
Southern	NULL
blotting	NULL
82	NULL
h	NULL
later	NULL
.	NULL

The	NULL
lane	NULL
labeled	NULL
-RT	NULL
contains	NULL
the	NULL
PCR	NULL
products	NULL
of	NULL
a	NULL
mock	NULL
reverse	NULL
transcriptase	NULL
reaction	NULL
with	NULL
the	NULL
Egr-3-transfected	NULL
RNA	NULL
sample	NULL
from	NULL
which	NULL
reverse	NULL
transcriptase	NULL
was	NULL
omitted	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
of	NULL
five	NULL
is	NULL
shown	NULL
.	NULL

the	NULL
wild	NULL
type	NULL
FLRE	NULL
was	NULL
minimally	NULL
affected	NULL
by	NULL
cotransfected	NULL
Egr-1	NULL
,	NULL
it	NULL
was	NULL
driven	NULL
by	NULL
Egr-3	NULL
and	NULL
even	NULL
more	NULL
strongly	NULL
by	NULL
Eigr-2	NULL
.	NULL

Thus	NULL
,	NULL
expression	NULL
of	NULL
either	NULL
Egr-2	NULL
or	NULL
Egr-3	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
the	NULL
fasL	NULL
promoter	NULL
,	NULL
and	NULL
this	NULL
response	NULL
does	NULL
not	NULL
require	NULL
the	NULL
presence	NULL
of	NULL
lymphoid-specific	NULL
accessory	NULL
factors	NULL
.	NULL

We	NULL
previously	NULL
showed	NULL
that	NULL
overexpression	NULL
of	NULL
Egr-3	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
the	NULL
appearance	NULL
of	NULL
fasL	NULL
mRNA	NULL
in	NULL
Hela	NULL
cells	NULL
.	NULL

Similar	NULL
experiments	NULL
were	NULL
performed	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
same	NULL
is	NULL
true	NULL
for	NULL
Egr-2	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
Egr-1	NULL
had	NULL
only	NULL
a	NULL
small	NULL
effect	NULL
on	NULL
fasL	NULL
mRNA	NULL
levels	NULL
as	NULL
measured	NULL
by	NULL
RT-PCR	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Egr-2	NULL
,	NULL
just	NULL
like	NULL
Egr-3	NULL
,	NULL
induced	NULL
easily	NULL
detectable	NULL
fasL	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
3226	NULL
212	NULL
225	NULL
m305	NULL
305	NULL
Vector	NULL
0	NULL
1000	NULL
2000	NULL
3000	NULL
4000	NULL
5000	NULL
Luciferase	NULL
units	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

An	NULL
intact	NULL
FLRE	NULL
is	NULL
required	NULL
for	NULL
optimal	NULL
constitutive	NULL
fasL-dependent	NULL
reporter	NULL
activity	NULL
in	NULL
lpr	NULL
lymph	NULL
node	NULL
DN	NULL
T	NULL
cells	NULL
.	NULL

Lpr	NULL
lymph	NULL
node	NULL
DN	NULL
T	NULL
cells	NULL
were	NULL
electroporated	NULL
with	NULL
the	NULL
indicated	NULL
fasL	NULL
promoter-driven	NULL
luciferase	NULL
reporter	NULL
plasmids	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
15	NULL
h	NULL
later	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
of	NULL
three	NULL
is	NULL
shown	NULL
.	NULL

mRNA	NULL
.	NULL

Thus	NULL
,	NULL
Egr-2	NULL
can	NULL
activate	NULL
fasL-specific	NULL
transcription	NULL
without	NULL
other	NULL
methods	NULL
of	NULL
cellular	NULL
activation	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
FLRE	NULL
Diminishes	NULL
Expression	NULL
of	NULL
fas	NULL
Reporters	NULL
in	NULL
Ipr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
Cells-To	NULL
determine	NULL
whether	NULL
the	NULL
FLRE	NULL
and	NULL
by	NULL
implication	NULL
Egr-2	NULL
are	NULL
necessary	NULL
for	NULL
the	NULL
up-regulation	NULL
of	NULL
FasL	NULL
in	NULL
lpr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
cells	NULL
,	NULL
these	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
reporter	NULL
constructs	NULL
driven	NULL
by	NULL
parts	NULL
of	NULL
the	NULL
fasL	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

A	NULL
reporter	NULL
containing	NULL
the	NULL
proximal	NULL
225	NULL
bp	NULL
of	NULL
the	NULL
fasL	NULL
gene	NULL
was	NULL
induced	NULL
to	NULL
a	NULL
much	NULL
greater	NULL
extent	NULL
than	NULL
one	NULL
containing	NULL
just	NULL
the	NULL
proximal	NULL
212	NULL
bp	NULL
(	NULL
and	NULL
thus	NULL
having	NULL
a	NULL
disrupted	NULL
Egr-binding	NULL
site	NULL
(	NULL
-214	NULL
to	NULL
-207	NULL
)	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
a	NULL
reporter	NULL
driven	NULL
by	NULL
a	NULL
larger	NULL
segment	NULL
of	NULL
the	NULL
promoter	NULL
(	NULL
305	NULL
bp	NULL
)	NULL
also	NULL
was	NULL
active	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
and	NULL
this	NULL
activity	NULL
was	NULL
largely	NULL
lost	NULL
by	NULL
mutation	NULL
of	NULL
the	NULL
FLRE	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
gld	NULL
DN	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
the	NULL
FLRE	NULL
,	NULL
principally	NULL
by	NULL
binding	NULL
the	NULL
constitutively	NULL
present	NULL
transcription	NULL
factor	NULL
Egr-2	NULL
,	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
maintenance	NULL
of	NULL
fasL	NULL
mRNA	NULL
expression	NULL
in	NULL
both	NULL
lpr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
cells	NULL
and	NULL
in	NULL
an	NULL
additional	NULL
context	NULL
confirm	NULL
the	NULL
role	NULL
of	NULL
this	NULL
site	NULL
in	NULL
fasL	NULL
regulation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
The	NULL
importance	NULL
of	NULL
the	NULL
FasL-triggered	NULL
apoptotic	NULL
death	NULL
pathway	NULL
for	NULL
T	NULL
cell	NULL
homeostasis	NULL
is	NULL
well	NULL
established	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
fasL	NULL
transcription	NULL
is	NULL
a	NULL
critical	NULL
control	NULL
point	NULL
in	NULL
this	NULL
phenome-non	NULL
.	NULL

A	NULL
single	NULL
Egr	NULL
family	NULL
binding	NULL
element	NULL
appears	NULL
to	NULL
account	NULL
for	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
activation-induced	NULL
cis-acting	NULL
regulation	NULL
of	NULL
fasL	NULL
(	NULL
20	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
identify	NULL
Egr-2	NULL
,	NULL
along	NULL
with	NULL
the	NULL
previously	NULL
identified	NULL
Egr-3	NULL
,	NULL
as	NULL
a	NULL
direct	NULL
regulator	NULL
of	NULL
fasL	NULL
transcription	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Like	NULL
Egr-3	NULL
,	NULL
this	NULL
factor	NULL
inducibly	NULL
binds	NULL
to	NULL
the	NULL
FLRE	NULL
in	NULL
the	NULL
fasL	NULL
promoter	NULL
and	NULL
is	NULL
synthesized	NULL
de	NULL
novo	NULL
in	NULL
a	NULL
CsA-sensitive	NULL
manner	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Ectopi-cally	NULL
expressed	NULL
Egr-2	NULL
,	NULL
like	NULL
Egr-3	NULL
,	NULL
was	NULL
sufficient	NULL
to	NULL
induce	NULL
fasL-specific	NULL
transcription	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
both	NULL
fasL	NULL
reporter	NULL
construct	NULL
activity	NULL
and	NULL
the	NULL
measurement	NULL
of	NULL
cellular	NULL
fasL	NULL
mRNA	NULL
.	NULL

Egr	NULL
family	NULL
genes	NULL
are	NULL
transcriptionally	NULL
up-regulated	NULL
from	NULL
low	NULL
basal	NULL
levels	NULL
in	NULL
response	NULL
to	NULL
a	NULL
multitude	NULL
of	NULL
cellular	NULL
stimuli	NULL
(	NULL
41	NULL
)	NULL
.	NULL

TCR	NULL
induction	NULL
of	NULL
Egr	NULL
family	NULL
gene	NULL
transcription	NULL
is	NULL
differentially	NULL
sensitive	NULL
to	NULL
CsA	NULL
;	NULL
transcription	NULL
of	NULL
Egr-2	NULL
and	NULL
Egr-3	NULL
is	NULL
sensitive	NULL
to	NULL
CsA	NULL
,	NULL
but	NULL
Egr-1	NULL
is	NULL
not	NULL
.	NULL

That	NULL
the	NULL
more	NULL
abundant	NULL
Egr-1	NULL
protein	NULL
does	NULL
not	NULL
up-regulate	NULL
fasL	NULL
was	NULL
confirmed	NULL
by	NULL
transient	NULL
expression	NULL
in	NULL
T	NULL
and	NULL
HeLa	NULL
cells	NULL
,	NULL
in	NULL
which	NULL
it	NULL
was	NULL
found	NULL
to	NULL
be	NULL
ineffective	NULL
at	NULL
inducing	NULL
fasL	NULL
reporter	NULL
constructs	NULL
and	NULL
fasL	NULL
mRNA	NULL
expression	NULL
.	NULL

Thus	NULL
,	NULL
by	NULL
these	NULL
criteria	NULL
Egr-2	NULL
and	NULL
Egr-3	NULL
are	NULL
the	NULL
likely	NULL
Egr	NULL
family	NULL
members	NULL
to	NULL
mediate	NULL
transcriptional	NULL
activation	NULL
through	NULL
the	NULL
FLRE	NULL
and	NULL
thus	NULL
are	NULL
likely	NULL
themselves	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
NF-AT	NULL
.	NULL

Little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
function	NULL
of	NULL
Egr-2	NULL
in	NULL
vivo	NULL
.	NULL

As	NULL
with	NULL
the	NULL
other	NULL
Egr	NULL
family	NULL
members	NULL
,	NULL
egr-2	NULL
mRNA	NULL
is	NULL
not	NULL
detected	NULL
in	NULL
Role	NULL
of	NULL
Egr-2	NULL
in	NULL
Up-regulation	NULL
of	NULL
Fas	NULL
Ligand	NULL
most	NULL
adult	NULL
tissues	NULL
by	NULL
Northern	NULL
analysis	NULL
.	NULL

An	NULL
exception	NULL
is	NULL
the	NULL
thymus	NULL
,	NULL
where	NULL
some	NULL
of	NULL
the	NULL
cells	NULL
are	NULL
undergoing	NULL
antigen-driven	NULL
selection	NULL
(	NULL
42	NULL
)	NULL
,	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
28	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Egr-2	NULL
is	NULL
also	NULL
expressed	NULL
in	NULL
the	NULL
course	NULL
of	NULL
embryogenesis	NULL
(	NULL
days	NULL
8-9	NULL
postcoitum	NULL
in	NULL
the	NULL
mouse	NULL
)	NULL
in	NULL
rhombomeres	NULL
r3	NULL
and	NULL
r5	NULL
of	NULL
the	NULL
hindbrain	NULL
.	NULL

Egr-2-deficient	NULL
mice	NULL
have	NULL
disruptions	NULL
of	NULL
these	NULL
rhombomeres	NULL
(	NULL
43	NULL
)	NULL
as	NULL
well	NULL
as	NULL
defects	NULL
in	NULL
myelination	NULL
of	NULL
peripheral	NULL
nerves	NULL
(	NULL
30	NULL
)	NULL
,	NULL
and	NULL
the	NULL
mice	NULL
are	NULL
nonviable	NULL
.	NULL

Proposed	NULL
target	NULL
genes	NULL
of	NULL
Egr-2	NULL
include	NULL
HoxB-2	NULL
and	NULL
HoxA-2	NULL
(	NULL
44	NULL
)	NULL
,	NULL
which	NULL
encode	NULL
homeobox	NULL
domain	NULL
transcription	NULL
factors	NULL
(	NULL
45	NULL
)	NULL
,	NULL
and	NULL
EphA4	NULL
,	NULL
which	NULL
encodes	NULL
a	NULL
receptor	NULL
tyrosine	NULL
kinase	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
mouse	NULL
embryos	NULL
with	NULL
retinoic	NULL
acid	NULL
,	NULL
which	NULL
activates	NULL
retinoic	NULL
acid	NULL
receptors	NULL
(	NULL
RARs/RXRs	NULL
)	NULL
that	NULL
are	NULL
themselves	NULL
transcription	NULL
factors	NULL
,	NULL
inhibits	NULL
egr-2	NULL
expression	NULL
in	NULL
rhombomere	NULL
3	NULL
and	NULL
prevents	NULL
maturation	NULL
of	NULL
this	NULL
hindbrain	NULL
segment	NULL
(	NULL
47-49	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
thymocytes	NULL
,	NULL
retinoic	NULL
acid	NULL
inhibits	NULL
activation-induced	NULL
fasL	NULL
up-regulation	NULL
and	NULL
apoptosis	NULL
(	NULL
50-52	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
retinoic	NULL
acid	NULL
inhibits	NULL
TCR-inducible	NULL
fasL	NULL
promoter	NULL
activity	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Thus	NULL
,	NULL
some	NULL
of	NULL
the	NULL
genetic	NULL
interrelationships	NULL
that	NULL
underlie	NULL
neural	NULL
development	NULL
may	NULL
be	NULL
recapitulated	NULL
in	NULL
that	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

The	NULL
aberrant	NULL
DN	NULL
T	NULL
cells	NULL
found	NULL
in	NULL
lpr	NULL
and	NULL
gld	NULL
mice	NULL
have	NULL
an	NULL
activated	NULL
phenotype	NULL
yet	NULL
are	NULL
refractory	NULL
to	NULL
stimuli	NULL
such	NULL
as	NULL
TCR	NULL
cross-linking	NULL
,	NULL
interleukin-2	NULL
,	NULL
CD28	NULL
,	NULL
PMA	NULL
,	NULL
and	NULL
phytohemagglu-tinin	NULL
(	NULL
53	NULL
)	NULL
.	NULL

The	NULL
activated	NULL
state	NULL
presumably	NULL
arises	NULL
from	NULL
continual	NULL
contact	NULL
with	NULL
self-antigens	NULL
because	NULL
of	NULL
the	NULL
inability	NULL
of	NULL
the	NULL
peripheral	NULL
T	NULL
cells	NULL
to	NULL
be	NULL
deleted	NULL
by	NULL
the	NULL
normal	NULL
Fas-dependent	NULL
mechanisms	NULL
.	NULL

DN	NULL
T	NULL
cells	NULL
spontaneously	NULL
turn	NULL
over	NULL
inositol	NULL
phosphates	NULL
(	NULL
54	NULL
)	NULL
,	NULL
display	NULL
elevated	NULL
tyrosine-phosphorylation	NULL
of	NULL
TCRE	NULL
(	NULL
55	NULL
)	NULL
and	NULL
Vav	NULL
(	NULL
56	NULL
)	NULL
,	NULL
and	NULL
express	NULL
increased	NULL
levels	NULL
of	NULL
the	NULL
tyrosine	NULL
kinase	NULL
Fyn	NULL
(	NULL
57	NULL
)	NULL
.	NULL

Also	NULL
increased	NULL
is	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
NF-kB	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
an	NULL
uncharacterized	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
NF-AT	NULL
,	NULL
,	NULL
that	NULL
recognized	NULL
the	NULL
DNA	NULL
sequence	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
NF-AT	NULL
site	NULL
(	NULL
58	NULL
)	NULL
.	NULL

DN	NULL
T	NULL
cells	NULL
do	NULL
not	NULL
proliferate	NULL
upon	NULL
TCR	NULL
cross-linking	NULL
in	NULL
part	NULL
because	NULL
they	NULL
are	NULL
unable	NULL
to	NULL
up-regulate	NULL
production	NULL
of	NULL
interleukin-2	NULL
(	NULL
59	NULL
)	NULL
.	NULL

To	NULL
account	NULL
for	NULL
this	NULL
,	NULL
it	NULL
was	NULL
proposed	NULL
that	NULL
NFAT	NULL
,	NULL
functions	NULL
as	NULL
a	NULL
transcriptional	NULL
repressor	NULL
that	NULL
overrides	NULL
the	NULL
activating	NULL
potential	NULL
of	NULL
the	NULL
aforementioned	NULL
constitutive	NULL
transcription	NULL
factors	NULL
activity	NULL
,	NULL
although	NULL
no	NULL
such	NULL
repressive	NULL
activity	NULL
was	NULL
demonstrated	NULL
(	NULL
58	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
egr-2	NULL
and	NULL
egr-3	NULL
promoters	NULL
NF-AT	NULL
,	NULL
,	NULL
functions	NULL
as	NULL
an	NULL
activator	NULL
of	NULL
transcription	NULL
.	NULL

Attempts	NULL
to	NULL
analyze	NULL
the	NULL
promoters	NULL
of	NULL
these	NULL
genes	NULL
are	NULL
currently	NULL
underway	NULL
.	NULL

By	NULL
Northern	NULL
analysis	NULL
,	NULL
Ipr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
cells	NULL
were	NULL
found	NULL
to	NULL
contain	NULL
elevated	NULL
egr-2	NULL
mRNA	NULL
levels	NULL
relative	NULL
to	NULL
activated	NULL
C3H	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

mRNA	NULL
for	NULL
egr-3	NULL
,	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
egr-1	NULL
,	NULL
was	NULL
less	NULL
abundant	NULL
in	NULL
DN	NULL
T	NULL
cells	NULL
than	NULL
in	NULL
activated	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
relative	NULL
levels	NULL
correlated	NULL
with	NULL
those	NULL
observed	NULL
by	NULL
gel	NULL
shift	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
activated	NULL
2B4.11	NULL
cells	NULL
contained	NULL
similar	NULL
amounts	NULL
of	NULL
Egr-2-	NULL
and	NULL
Egr-3-specific	NULL
FLRE	NULL
binding	NULL
activity	NULL
.	NULL

Thus	NULL
,	NULL
of	NULL
the	NULL
Egr	NULL
family	NULL
members	NULL
capable	NULL
of	NULL
inducing	NULL
fasL	NULL
transcription	NULL
,	NULL
Egr-2	NULL
is	NULL
selectively	NULL
expressed	NULL
in	NULL
lpr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
cells	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
Egr	NULL
family	NULL
member	NULL
expression	NULL
is	NULL
thus	NULL
another	NULL
characteristic	NULL
distinguishing	NULL
the	NULL
chronic	NULL
state	NULL
of	NULL
activation	NULL
of	NULL
lpr	NULL
and	NULL
gld	NULL
DN	NULL
T	NULL
cells	NULL
from	NULL
that	NULL
of	NULL
normal	NULL
T	NULL
cells	NULL
responding	NULL
acutely	NULL
to	NULL
antigen	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
correlation	NULL
between	NULL
the	NULL
signaling	NULL
pathways	NULL
constitutively	NULL
activated	NULL
and	NULL
the	NULL
Egr	NULL
family	NULL
members	NULL
expressed	NULL
in	NULL
DN	NULL
T	NULL
cells	NULL
will	NULL
further	NULL
understanding	NULL
of	NULL
both	NULL
normal	NULL
and	NULL
abnormal	NULL
TCR	NULL
signaling	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Suda	NULL
,	NULL
T.	NULL
,	NULL
Takahashi	NULL
,	NULL
T.	NULL
,	NULL
Golstein	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Nagata	NULL
,	NULL
S.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
75	NULL
,	NULL
1169-1178	NULL
2	NULL
.	NULL

Irmler	NULL
,	NULL
M.	NULL
,	NULL
Thome	NULL
,	NULL
M.	NULL
,	NULL
Hahne	NULL
,	NULL
M.	NULL
,	NULL
Schneider	NULL
,	NULL
P.	NULL
,	NULL
Hofmann	NULL
,	NULL
K.	NULL
,	NULL
Steiner	NULL
,	NULL
V.	NULL
,	NULL
Bodmer	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Schroter	NULL
,	NULL
M.	NULL
,	NULL
Burns	NULL
,	NULL
K.	NULL
,	NULL
Mattmann	NULL
,	NULL
C.	NULL
,	NULL
Rimoldi	NULL
,	NULL
D.	NULL
,	NULL
French	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
and	NULL
Tschopp	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Nature	NULL
388	NULL
,	NULL
190-195	NULL
3	NULL
.	NULL

Deveraux	NULL
,	NULL
Q.	NULL
L.	NULL
,	NULL
Takahashi	NULL
,	NULL
R.	NULL
,	NULL
Salvesen	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
and	NULL
Reed	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
388	NULL
,	NULL
300-304	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

18	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

Role	NULL
of	NULL
Egr-2	NULL
in	NULL
Up-regulation	NULL
of	NULL
Fas	NULL
Ligand	NULL
.	NULL

Duckett	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Li	NULL
,	NULL
F.	NULL
,	NULL
Wang	NULL
,	NULL
Y.	NULL
,	NULL
Tomaselli	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
and	NULL
Armstrong	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
608-615	NULL
.	NULL

Watanabe-Fukunaga	NULL
,	NULL
R.	NULL
,	NULL
Brannan	NULL
,	NULL
C.	NULL
I.	NULL
,	NULL
Copeland	NULL
,	NULL
N.	NULL
G.	NULL
,	NULL
Jenkins	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Nagata	NULL
,	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
856	NULL
,	NULL
314-317	NULL
.	NULL

Takahashi	NULL
,	NULL
T.	NULL
,	NULL
Tanaka	NULL
,	NULL
M.	NULL
,	NULL
Brannan	NULL
,	NULL
C.	NULL
I.	NULL
,	NULL
Jenkins	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Copeland	NULL
,	NULL
N.	NULL
G.	NULL
,	NULL
Suda	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Nagata	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
969-976	NULL
.	NULL

Lynch	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Watson	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Alderson	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Baum	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Miller	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Tough	NULL
,	NULL
T.	NULL
,	NULL
Gibson	NULL
,	NULL
M.	NULL
,	NULL
Davis-Smith	NULL
,	NULL
T.	NULL
,	NULL
Smith	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Hunter	NULL
,	NULL
K.	NULL
,	NULL
Bhat	NULL
,	NULL
D.	NULL
,	NULL
Din	NULL
,	NULL
W.	NULL
,	NULL
Goodwin	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
and	NULL
Seldin	NULL
,	NULL
M.	NULL
F.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
181-136	NULL
.	NULL

Hahne	NULL
,	NULL
M.	NULL
,	NULL
Peitsch	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Irmler	NULL
,	NULL
M.	NULL
,	NULL
Schroter	NULL
,	NULL
M.	NULL
,	NULL
Lowin	NULL
,	NULL
B.	NULL
,	NULL
Rousseau	NULL
,	NULL
M.	NULL
,	NULL
Bron	NULL
,	NULL
C.	NULL
,	NULL
Renno	NULL
,	NULL
T.	NULL
,	NULL
French	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Tschopp	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
1381-1386	NULL
.	NULL

Rieux-Laucat	NULL
,	NULL
F.	NULL
,	NULL
Le	NULL
Deist	NULL
,	NULL
F.	NULL
,	NULL
Hivroz	NULL
,	NULL
C.	NULL
,	NULL
Roberts	NULL
,	NULL
I	NULL
.	NULL

A.	NULL
G.	NULL
,	NULL
Debatin	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Fischer	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
de	NULL
Villartay	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
268	NULL
,	NULL
1347-1349	NULL
Fisher	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
Rosenberg	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Straus	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Dale	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Middelton	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Lin	NULL
,	NULL
A.	NULL
Y.	NULL
,	NULL
Strober	NULL
,	NULL
W.	NULL
,	NULL
Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Puck	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
81	NULL
,	NULL
935-946	NULL
Drappa	NULL
,	NULL
J.	NULL
,	NULL
Vaishnaw	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
Sullivan	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Chu	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Elkon	NULL
,	NULL
K.	NULL
B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

885	NULL
,	NULL
1648-1649	NULL
Watanabe	NULL
,	NULL
D.	NULL
,	NULL
Suda	NULL
,	NULL
T.	NULL
,	NULL
Hashimoto	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Nagata	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

14	NULL
,	NULL
12-18	NULL
Chu	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Ramos	NULL
,	NULL
P.	NULL
,	NULL
Rosendorff	NULL
,	NULL
A.	NULL
,	NULL
Nikolic-Zugic	NULL
,	NULL
J.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
Matsuzawa	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Elkon	NULL
,	NULL
K.	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
398-398	NULL
Kasibhatla	NULL
,	NULL
S.	NULL
,	NULL
Brunner	NULL
,	NULL
T.	NULL
,	NULL
Genestier	NULL
,	NULL
L.	NULL
,	NULL
Echeverri	NULL
,	NULL
F.	NULL
,	NULL
Mahboubi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

1	NULL
,	NULL
548-551	NULL
Palombella	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
Rando	NULL
,	NULL
O.	NULL
J.	NULL
,	NULL
Goldberg	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
78	NULL
,	NULL
T13-785	NULL
Matsui	NULL
,	NULL
K.	NULL
,	NULL
Omura	NULL
,	NULL
S.	NULL
,	NULL
Cui	NULL
,	NULL
H.	NULL
,	NULL
Schauer	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Sonenshein	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
and	NULL
Ju	NULL
,	NULL
S.	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27	NULL
,	NULL
2269-2278	NULL
Williams	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
Henkart	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J	NULL
Immunol	NULL
157	NULL
,	NULL
2395-2402	NULL
Bauer	NULL
,	NULL
M.	NULL
K.	NULL
A.	NULL
,	NULL
Vogt	NULL
,	NULL
M.	NULL
,	NULL
Los	NULL
,	NULL
M.	NULL
,	NULL
Siegel	NULL
,	NULL
J.	NULL
,	NULL
Wesselborg	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Schulze-Osthoff	NULL
,	NULL
K.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
8048-8055	NULL
Takahashi	NULL
,	NULL
T.	NULL
,	NULL
Tanaka	NULL
,	NULL
M.	NULL
,	NULL
Inazawa	NULL
,	NULL
J.	NULL
,	NULL
Abe	NULL
,	NULL
T.	NULL
,	NULL
Suda	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Nagata	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
1567-1574	NULL
Mittelstadt	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
and	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
8744-3751	NULL
Latinis	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Carr	NULL
,	NULL
L.	NULL
L.	NULL
,	NULL
Peterson	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Norian	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Eliason	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Koretzky	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
4602-4611	NULL
Latinis	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Norian	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Eliason	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Koretzky	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
81427-81484	NULL
Rouvier	NULL
,	NULL
E.	NULL
,	NULL
Luciani	NULL
,	NULL
M.-F.	NULL
,	NULL
and	NULL
Golstein	NULL
,	NULL
P.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177	NULL
,	NULL
195-200	NULL
Brunner	NULL
,	NULL
T.	NULL
,	NULL
Yoo	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
LaFace	NULL
,	NULL
D.	NULL
,	NULL
Ware	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
1017-1026	NULL
Hodge	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Ranger	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Charles	NULL
de	NULL
la	NULL
Brousse	NULL
,	NULL
F.	NULL
,	NULL
Hoey	NULL
,	NULL
T.	NULL
,	NULL
Grusby	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
(	NULL
1996	NULL
)	NULL
Immunity	NULL
4	NULL
,	NULL
397-405	NULL
Holtz-Heppelmann	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Algeciras	NULL
,	NULL
A.	NULL
,	NULL
Badley	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
and	NULL
Paya	NULL
,	NULL
C.	NULL
V.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
4416-4423	NULL
Skerka	NULL
,	NULL
C.	NULL
,	NULL
Decker	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
and	NULL
Zipfel	NULL
,	NULL
P.	NULL
F.	NULL
(	NULL
1997	NULL
)	NULL
Immunobiology	NULL
198	NULL
,	NULL
179-191	NULL
Mages	NULL
,	NULL
H.	NULL
W.	NULL
,	NULL
Stamminger	NULL
,	NULL
T.	NULL
,	NULL
Rilke	NULL
,	NULL
O.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Kroczek	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

5	NULL
,	NULL
63-70	NULL
Swirnoff	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
and	NULL
Milbrandt	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
2275-2287	NULL
Topilko	NULL
,	NULL
P.	NULL
,	NULL
Levi	NULL
,	NULL
G.	NULL
,	NULL
Merlo	NULL
,	NULL
G.	NULL
,	NULL
Mantero	NULL
,	NULL
S.	NULL
,	NULL
Desmarquet	NULL
,	NULL
C.	NULL
,	NULL
Mancardi	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Charnay	NULL
,	NULL
P.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Newrosci	NULL
.	NULL

Res	NULL
.	NULL

50	NULL
,	NULL
702-712	NULL
Hedrick	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Matis	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Hecht	NULL
,	NULL
T.	NULL
T.	NULL
,	NULL
Samelson	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Heber-Katz	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
141-152	NULL
Russo	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Matheny	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Milbrandt	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
6858-6865	NULL
33	NULL
34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

3227	NULL
.	NULL

Boshart	NULL
,	NULL
M.	NULL
,	NULL
Weber	NULL
,	NULL
F.	NULL
,	NULL
Jahn	NULL
,	NULL
G.	NULL
,	NULL
Dorsch-Hasler	NULL
,	NULL
K.	NULL
,	NULL
Fleckenstein	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
Cell	NULL
41	NULL
,	NULL
521-530	NULL
Ausubel	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Brent	NULL
,	NULL
R.	NULL
,	NULL
Kingston	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Moore	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
Seidman	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Smith	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Struhl	NULL
,	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
Current	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
,	NULL
Vol	NULL
.	NULL

9	NULL
,	NULL
John	NULL
Wiley	NULL
and	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
Church	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
and	NULL
Gilbert	NULL
,	NULL
W.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

81	NULL
,	NULL
1991-1995	NULL
Yang	NULL
,	NULL
Y.	NULL
,	NULL
Mercep	NULL
,	NULL
M.	NULL
,	NULL
Ware	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
and	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
1673-1682	NULL
Giese	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Davidson	NULL
,	NULL
W.	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

149	NULL
,	NULL
3097-3106	NULL
Liu	NULL
,	NULL
J.	NULL
,	NULL
Farmer	NULL
,	NULL
J.	NULL
D.	NULL
J.	NULL
,	NULL
Lane	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Friedman	NULL
,	NULL
J.	NULL
,	NULL
Weissman	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
807-815	NULL
Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
695-697	NULL
Shao	NULL
,	NULL
H.	NULL
,	NULL
Kono	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Chen	NULL
,	NULL
L.	NULL
Y.	NULL
,	NULL
Rubin	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
Kaye	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185	NULL
,	NULL
731-744	NULL
Gashler	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Sukhatme	NULL
,	NULL
V.	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Prog	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

50	NULL
,	NULL
191-224	NULL
Chavrier	NULL
,	NULL
P.	NULL
,	NULL
Zerial	NULL
,	NULL
M.	NULL
,	NULL
Lemaire	NULL
,	NULL
P.	NULL
,	NULL
Almendral	NULL
,	NULL
J.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Charnay	NULL
,	NULL
P.	NULL
(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
29-35	NULL
Schneider-Maunoury	NULL
,	NULL
S.	NULL
,	NULL
Topilko	NULL
,	NULL
P.	NULL
,	NULL
Seitandou	NULL
,	NULL
T.	NULL
,	NULL
Levi	NULL
,	NULL
G.	NULL
,	NULL
Cohen-Tannoudji	NULL
,	NULL
M.	NULL
,	NULL
Pournin	NULL
,	NULL
S.	NULL
,	NULL
Babinet	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Charnay	NULL
,	NULL
P.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
75	NULL
,	NULL
1199-1214	NULL
.	NULL

Nonchev	NULL
,	NULL
S.	NULL
,	NULL
Vesque	NULL
,	NULL
C.	NULL
,	NULL
Maconochie	NULL
,	NULL
M.	NULL
,	NULL
Seitanidou	NULL
,	NULL
T.	NULL
,	NULL
Ariza-McNaughton	NULL
,	NULL
L.	NULL
,	NULL
Frain	NULL
,	NULL
M.	NULL
,	NULL
Marshall	NULL
,	NULL
H.	NULL
,	NULL
Sham	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Krumlauf	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Charnay	NULL
,	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
Development	NULL
122	NULL
,	NULL
548-554	NULL
Sham	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Vesque	NULL
,	NULL
C.	NULL
,	NULL
Nonchev	NULL
,	NULL
S.	NULL
,	NULL
Marshall	NULL
,	NULL
H.	NULL
,	NULL
Frain	NULL
,	NULL
M.	NULL
,	NULL
Gupta	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Whiting	NULL
,	NULL
J.	NULL
,	NULL
Wilkinson	NULL
,	NULL
D.	NULL
,	NULL
Charnay	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Krumlauf	NULL
,	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Cell	NULL
72	NULL
,	NULL
183-196	NULL
Theil	NULL
,	NULL
T.	NULL
,	NULL
Frain	NULL
,	NULL
M.	NULL
,	NULL
Gilardi-Hebenstreit	NULL
,	NULL
P.	NULL
,	NULL
Flenniken	NULL
,	NULL
A.	NULL
,	NULL
Charnay	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Wilkinson	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
Development	NULL
125	NULL
,	NULL
448-452	NULL
Marshall	NULL
,	NULL
H.	NULL
,	NULL
Nonchev	NULL
,	NULL
S.	NULL
,	NULL
Sham	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Muchamore	NULL
,	NULL
I.	NULL
,	NULL
Lumsden	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Krumlauf	NULL
,	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
360	NULL
,	NULL
737-741	NULL
Morriss-Kay	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Murphy	NULL
,	NULL
P.	NULL
,	NULL
Hill	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
Davidson	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
2985-2995	NULL
Nittenberg	NULL
,	NULL
R.	NULL
,	NULL
Patel	NULL
,	NULL
K.	NULL
,	NULL
Joshi	NULL
,	NULL
Y.	NULL
,	NULL
Krumlauf	NULL
,	NULL
R.	NULL
,	NULL
Wilkinson	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Brickell	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Tickle	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Clarke	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
Development	NULL
124	NULL
,	NULL
2297-2306	NULL
Yang	NULL
,	NULL
Y.	NULL
,	NULL
Minucci	NULL
,	NULL
S.	NULL
,	NULL
Ozato	NULL
,	NULL
K.	NULL
,	NULL
Heyman	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
18672-18677	NULL
Iwata	NULL
,	NULL
M.	NULL
,	NULL
Mukai	NULL
,	NULL
M.	NULL
,	NULL
Nakai	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Iseki	NULL
,	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

149	NULL
,	NULL
3302-3308	NULL
Schile	NULL
,	NULL
R.	NULL
,	NULL
Rangarajan	NULL
,	NULL
P.	NULL
,	NULL
Yang	NULL
,	NULL
N.	NULL
,	NULL
Kliewer	NULL
,	NULL
S.	NULL
,	NULL
Ransone	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Bolado	NULL
,	NULL
J.	NULL
,	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
6092-6096	NULL
Giese	NULL
,	NULL
T.	NULL
,	NULL
Allison	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Davidson	NULL
,	NULL
W.	NULL
F.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
597-609	NULL
Tomita-Yamaguchi	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Santoro	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
3946-8952	NULL
Samelson	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Davidson	NULL
,	NULL
W.	NULL
F.	NULL
,	NULL
Morse	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
III	NULL
,	NULL
and	NULL
Klausner	NULL
,	NULL
R.	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Nature	NULL
824	NULL
,	NULL
674-676	NULL
Mimura	NULL
,	NULL
T.	NULL
,	NULL
Minota	NULL
,	NULL
S.	NULL
,	NULL
Nojima	NULL
,	NULL
Y.	NULL
,	NULL
Morino	NULL
,	NULL
N.	NULL
,	NULL
Hamasaki	NULL
,	NULL
K.	NULL
,	NULL
Furuya	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
.	NULL

Yazaki	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
2977-2983	NULL
Katagiri	NULL
,	NULL
T.	NULL
,	NULL
Urakawa	NULL
,	NULL
K.	NULL
,	NULL
Yamanashi	NULL
,	NULL
V.	NULL
,	NULL
Semba	NULL
,	NULL
K.	NULL
,	NULL
Takahashi	NULL
,	NULL
T.	NULL
,	NULL
Toyoshima	NULL
,	NULL
K.	NULL
,	NULL
Yamamoto	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Kano	NULL
,	NULL
K.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

86	NULL
,	NULL
10064-10068	NULL
Clements	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Cooper	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Budd	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

154	NULL
,	NULL
6372-6381	NULL
Davignon	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Budd	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Ceredig	NULL
,	NULL
R.	NULL
,	NULL
Piguet	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
MacDonald	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
Cerottini	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Vassalli	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Izui	NULL
,	NULL
S.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

185	NULL
,	NULL
2423-2428	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Role	NULL
of	NULL
Egr-2	NULL
in	NULL
Up-regulation	NULL
of	NULL
Fas	NULL
Ligand	NULL
in	NULL
Normal	NULL
T	NULL
Cells	NULL
and	NULL
Aberrant	NULL
Double-negative	NULL
Ipr	NULL
and	NULL
gid	NULL
T	NULL
Cells	NULL
Paul	NULL
R.	NULL
Mittelstadt	NULL
and	NULL
Jonathan	NULL
D.	NULL
Ashwell	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
,	NULL
274:3222-3227.	NULL
doi	NULL
:	NULL
10.1074/jb0.274.5.3222	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/274/5/3222	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
58	NULL
references	NULL
,	NULL
27	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
full.html	NULL
#	NULL
ref-list-	NULL
1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

